

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 March 2004 (25.03.2004)

PCT

(10) International Publication Number
WO 2004/024922 A1

(51) International Patent Classification⁷: **C12N 15/15**,
C07K 14/81, G01N 33/53

SHOEMAKER, Charles, Bix [US/NZ]; 9a Hildreth
Street, 6007 Upper Hutt (NZ).

(21) International Application Number:
PCT/NZ2003/000205

(74) Agents: **WILSON, Kathryn, Shelley** et al.; Private Bag
3140, Level 12, KPMG Centre, 85 Alexandra Street, 2001
Hamilton (NZ).

(22) International Filing Date:
12 September 2003 (12.09.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
521434 13 September 2002 (13.09.2002) NZ
523777 24 January 2003 (24.01.2003) NZ

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **OVITA
LIMITED** [NZ/NZ]; P.O.Box 5520, Dunedin, Level 4 NZI
House, 9 Moray Place, Dunedin (NZ).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MCNEILL, Mar-
garet, Mary** [NZ/NZ]; 7 Damian Grove, 6009 Lower
Hutt (NZ). **SHAW, Richard, John** [NZ/NZ]; 3 Skippage
Grove, 5952 Featherston (NZ). **MAASS, David, Richard**
[US/NZ]; 14 Plantagenet Grove, 6007 Upper Hutt (NZ).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: ASPARTYL PROTEASE INHIBITOR AS A NEMATODE ALLERGEN

(57) Abstract: The present invention is broadly directed to novel nematode allergens (polypeptides) and associated amino acid and nucleotide sequences including functional fragments and variants thereof to identify animals that are capable of becoming naturally resistant to nematodes. In particular, the present invention concerns the use of these molecules to, assist in selective breeding of animals capable of becoming naturally resistant to nematode infections. More, particularly, the invention is directed towards the use of nucleic acid molecules and polypeptides, which are the same or functional variants of, aspartyl protease inhibitors: (Tco-Aspin), of *Trichostrongylus colubriformis*; and/or (Oc-Aspin), of *Ostertagia circumcincta*; and/or (Hc-Aspin) *Haemonchus contortus* in identifying animals that are innately more disposed to nematodes.



WO 2004/024922 A1

Aspartyl protease inhibitor as a nematode allergen

TECHNICAL FIELD

The present invention relates to novel allergens. The present invention is broadly directed to novel nematode allergens (polypeptides) and associated amino acid and nucleotide sequences including functional fragments and variants thereof. The invention broadly concerns allergens obtained from, nematodes of the superfamily *Trichostrongyloidea*. In particular, the present invention concerns the use of the above molecules to identify animals that are naturally resistant to parasitic nematodes to assist with selective breeding of animals that are innately more disposed to develop immune resistance to, in particular but by no means exclusively, nematode infections in sheep and cattle.

BACKGROUND TO THE INVENTION

The molecules of the present invention are most preferably, but not necessarily exclusively, derived from *Ostertagia circumcincta* (*Teladorsagia circumcincta*) and *Trichostrongylus colubriformis* and have application in reducing the impact of these nematodes or similar nematodes on animals as discussed herein. For ease of reference only the background to the present invention will now be described in relation to *Trichostrongylus colubriformis* infection. However, it will be appreciated by those skilled in the art that such description is also of general application to most nematodes of the superfamily *Trichostrongyloidea*.

Trichostrongylus colubriformis is a nematode parasite which infects the small intestine of sheep and is of significant economic importance in New Zealand and many other countries worldwide. These parasites have a simple life cycle consisting of free-living stages on pasture (egg to infective larvae, L3), and after ingestion, develop through L4-L5-adult in the host gastrointestinal tract. They do not have a tissue migratory phase. *T. colubriformis* live in mucus covered tunnels eroded on the surface of duodenal and intestinal villi.

Presently the only effective means of controlling *T. colubriformis* and other nematodes that infect sheep is through the use of anthelmintics.

Sheep can develop natural immunity to *T. colubriformis* following repeated natural infections. Development of immunity to nematode establishment requires at least seven weeks of continuous infection (Dobson et al 1990). Thus, in the past sheep were effectively immunised by two or three periods of truncated infections, each followed by a treatment with an anthelmintic to remove infection 10-14 days later.

However, a major drawback with conventional anthelmintics is that nematode resistance to a broad spectrum of anthelmintics is now becoming increasingly more widespread and is therefore of serious concern. (Waller, 1997; Sangster *et al*, 1999; Van Wyk *et al*, 1999).

Various studies have suggested that immunity to *T. colubriformis* involve the development of Th2-type immune responses involving hypersensitivity type events. These responses include increased mast cell, globule leucocytes and eosinophil numbers in the intestinal mucosa. Elevated serum IgE levels have also been associated with immunity to nematode infections (Shaw et al., 1998a & b). One possible role of parasite-specific IgE in resistance to nematode infection is its involvement in immediate hypersensitivity reactions, where cross-linking of specific IgE on mucosal mast cells by antigen promotes their degranulation, which in sheep results in the formation of globule leukocytes. The resultant release of inflammatory mediators is considered to be a major mechanism involved in the rejection of parasites in immune sheep. The release of inflammatory mediators may cause a deterioration of the intestinal microenvironment and consequent expulsion of nematode parasites. The inflammatory response may also allow the leakage of immunoglobulins into the intestinal lumen and which may also assist in the expulsion of nematodes from the gastrointestinal tract.

Antigens that elicit hypersensitivity reactions by binding to IgE (i.e. allergens) are therefore useful in diagnostic assays to identify immune animals with a Th2-type hypersensitivity immune response. Thus, such antigens are useful in selective breeding programs for producing animals that are resistant to nematodes.

A major novel allergen of *Trichostrongylus colubriformis*, Tco-Aspin with a molecular weight of 31 kDa, pI 5.1 on 2-D electrophoresis gels has been identified by the inventors and its nucleotide and polypeptide sequence determined. It shares a degree of homology with a

number of proteins identified as nematode aspartyl protease inhibitors. From *Onchocerca*
volvulus an aspartyl protease inhibitor-like protein has been cloned by a number of
investigators. Ov33-3 (Lucius, et al., 1988) an immunodominant antigen recognised by 96% of
onchocerciasis patients; Oc3.6 (Chandrashekar, et al., 1991); OvD5B (Celine Nkenfou, Thesis,
5 "Molecular Cloning of Genes Coding Antigens Specific For *Onchocerca volvulus*: Evaluation of
Expressed Proteins For Use In The Diagnosis Of Onchocerciasis" University of Cameroon
(1993). Orthologs have been found in *Brugia malayi* (Bm33) (Dissanayake 1993),
Acanthocheilonevma viteae (Av33) (Willenbacher, et al., 1993), *Dirofilaria immitis* (DiT33) (Maja,
et al., 1994, Frank et al., 1998), *Parelaphostrongylus tenuis* (Ptpi) (Duffy et al., 2002) and
10 *Ostertagia ostertagi* (Claerebout et al., 2002) .

Some of these have been used successfully to diagnose important filarial infections of humans
including *O. volvulus* (Chandrashekar, et al., 1991 & 1996) and *B. malayi* (Chandrashekar, et
al., 1994; Dissanayake , et al., 1993).

However, at present there remains a need to identify allergens for nematode infections in
15 animals, particularly sheep and cattle, and which can be used to diagnose those animals which
are naturally inclined to develop immune resistance to nematode infection. Thus, the existence
of such allergens may be useful in selective breeding programs for animals innately more
disposed to develop immune resistance.

It is an object of the present invention to address the foregoing problems or at least to provide
20 the public with a useful choice.

Further aspects and advantages of the present invention will become apparent from the
ensuing description which is given by way of example only.

All references, including any patents or patent applications, cited in this specification are hereby
incorporated by reference. No admission is made that any reference constitutes prior art. The
25 discussion of the references states what their authors assert, and the applicants reserve the
right to challenge the accuracy and pertinency of the cited documents. It will be clearly
understood that, although a number of prior art publications are referred to herein, this

reference does not constitute an admission that any of these documents form part of the common general knowledge in the art, in New Zealand or in any other country.

SUMMARY OF INVENTION

5 The present invention is broadly directed to novel nematode allergens (polypeptides) and associated amino acid and nucleotide sequences including functional fragments and variants thereof to identify animals that are capable of becoming naturally resistant to nematodes. In particular, the present invention concerns the use of these molecules to, assist in selective breeding of animals capable of becoming naturally resistant to nematode infections. More, particularly, the invention is directed towards the use of nucleic acid molecules and
10 polypeptides, which are the same or functional variants of, aspartyl protease inhibitors: (Tco-Aspin), of *Trichostrongylus colubriformis*; and/or (Oc-Aspin), of *Ostertagia circumcincta*; and/or (Hc-Aspin) *Haemonchus contortus* in identifying animals that are innately more disposed to develop immune resistance to nematodes.

The inventors have identified a number of IgE binding antigens (allergens) of *T. colubriformis*,
15 *O. circumcincta* and *H. contortus*, using western blotting techniques with purified IgE from various immune animals. Using 2-D electrophoresis, the target allergens have been isolated and identified using mass spectrometry. Recombinant allergen proteins were prepared and tested for their ability to bind IgE from the serum of animals with a history of nematode infection.

DISCLOSURE OF INVENTION

20 According to a first aspect of the present invention there is provided an isolated polypeptide comprising:

- a) an amino acid sequence as set forth in any one of SEQ ID NOs. 1, 3, 5 or 7; or
- b) a functional fragment or variant of the polypeptides in a) above, wherein the fragment or variant provokes a humoral and/or cellular immunological response in
25 an animal with similar characteristics to that produced by a polypeptide of as outlined in a) above.

According to a second aspect of the present invention there is provided an isolated polypeptide substantially as described above wherein the functional fragment or variant incorporates a B cell or T cell epitope of the polypeptide.

In general the polypeptide may be derived from a nematode parasite of the superfamily
5 Trichostrongyloidea. However, it should also be appreciated that the polypeptide may also be artificially synthesized for example recombinantly synthesized

In particular, the polypeptide and/or nucleic acid molecule may be selected from a nematode parasite from the genera consisting of *Trichostrongylus*, *Cooperia*, *Dictyocaulus*, *Haemonchus*, *Ostertagia* or *Teladorsagia*.

10 Preferably, the nematode parasite maybe of the genera *Trichostrongylus* or *Ostertagia* preferably selected from the species consisting of either *T. colubriformis* or *O. circumcincta* (*Teladorsagia circumcincta*).

In a third aspect of the present invention there is provided an isolated nucleic acid molecule wherein the molecule:

- 15 a) comprises a nucleotide sequence as set forth in any one of SEQ ID NOs. 2, 4, 6 or 8;
- b) is a functional fragment or variant of the molecule(s) in a); or
- c) is able to hybridise under stringent conditions to the molecule(s) in a) or b); or
- d) is a complement of the molecule(s) defined in a), b) or c); or
- 20 e) is an anti-sense sequence corresponding to any of the sequences in a) – d).

In a fourth aspect of the present invention there is provided an isolated nucleic acid molecule encoding a polypeptide substantially as described above.

In a fifth aspect of the present invention there is provided a vector or construct comprising the nucleic acid molecule of the present invention.

In a sixth aspect of the present invention there is provided a host cell which has been transformed with a vector or construct of the present invention.

In an seventh aspect of the present invention there is provided an isolated ligand which binds to a polypeptide of the present invention.

- 5 In a eighth aspect of the present invention there is provided a probe capable of hybridizing under stringent conditions to a nucleic acid molecule of the present invention.

In a ninth aspect of the present invention there is provided a probe for a polypeptide substantially as described above.

- 10 In a tenth aspect of the present invention there is provided a probe for a ligand substantially as described above when said ligand is bound to a polypeptide of the present invention.

In an eleventh aspect of the present invention there is provided a method for determining the immune status of an animal to a nematode infection characterized by steps of:

- a) obtaining a blood or serum sample from the animal;
- b) preparing an IgE enriched or IgG depleted preparation of the sample in a);
- 15 c) contacting the sample at a) with a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs. 1, 3, 5 or 7 or a functional fragment or variant thereof;
- d) contacting the preparation from c) with a probe for the immuno-complex formed by IgE and the polypeptide;
- 20 e) detecting the probe to identify the immune status of the animal by the presence or absence of the probe.

In a twelfth aspect of the present invention there is provided a method for determining the immune status of an animal to a nematode infection characterized by steps of:

- a) obtaining a blood or serum sample from the animal

- b) preparing an IgE enriched or IgG depleted preparation of the sample in a);
- c) exposing the preparation from b) with a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs. 1, 3, 5 or 7 or a functional fragment or variant thereof ;
- 5 d) washing the preparation from c) to remove any unbound IgE (i.e. IgE that is not bound to the polypeptide);
- e) detection of immuno-complex formed by the polypeptide and IgE at step c) with monoclonal antibodies to IgE.
- f) detection of IgE with appropriately labeled anti-antibodies.
- 10 Preferably, at step b) the blood or serum is IgE enriched or IgG depleted using ammonium sulphate precipitation or affinity purification of sheep IgE. However, this should not be seen as limiting.

Preferably, the exposure step c) may be performed by coating the polypeptide of SEQ ID NO. 1 onto microtiter plates. However, other suitable methods for exposing are of course envisaged.

- 15 In preferred embodiments, the monoclonal antibodies of step d) may be mouse monoclonal antibodies. However, antibodies sourced from other animals may also be used without departing from the scope of the present invention.

Preferably, the sample may be exposed to the polypeptide via an enzyme-linked immunoassay (ELISA) or other suitable type of assay.

20

According to a thirteenth aspect there is provided a method of determining the immune status of an animal comprising the steps of:

- a) exposing a portion of the animal's skin to a polypeptide of the present invention;

- b) determining the immune status by the presence or absence of an immune or allergic reaction.

According to a fourteenth aspect there is provided a method for selectively breeding animals resistant to nematode infection characterized by steps of:

- 5 a) determining the immune status of male and female animals;
- b) selecting males and females disposed to develop immune resistance to nematodes;
- c) using selected animals to breed progeny resistant to said infection.

10 In general, the animal may be selected from sheep, goats, cattle and equines. However, this list should not be seen as limiting as the animal may be any mammal which is prone to infection with nematode parasites.

Preferably the animal may be selected from either cattle or sheep. Most preferably the animal may be a sheep.

15 In a fifteenth aspect of the present invention there is provided an isolated polypeptide substantially as described above wherein the polypeptide is a functional fragment or variant of SEQ ID NO. 5 having at least 90% homology to SEQ ID NO. 5.

In a sixteenth aspect of the present invention there is provided an isolated nucleic acid molecule substantially as described above wherein the molecule is a functional fragment or variant of SEQ ID NO. 6 having at least 94% homology to SEQ ID NO. 6.

20 In a seventeenth aspect of the present invention there is provided an isolated polypeptide substantially as described above wherein the polypeptide is a functional fragment or variant of SEQ ID NO. 1 having at least substantially 75% homology to SEQ ID NO. 1.

In an eighteenth aspect of the present invention there is provided an isolated nucleic acid molecule substantially as described above wherein the molecule is a functional fragment or
25 variant of SEQ ID NO. 2 having at least substantially 70% homology to SEQ ID NO. 2.

In a nineteenth aspect of the present invention there is provided an isolated polypeptide substantially as described above wherein the polypeptide is a functional fragment or variant of SEQ ID NO. 3 having at least 80% homology to SEQ ID NO. 3.

5 In a twentieth aspect of the present invention there is provided an isolated nucleic acid molecule substantially as described above wherein the molecule is a functional fragment or variant of SEQ ID NO. 4 having at least substantially 70% homology to SEQ ID NO. 4.

In a twenty-first aspect of the present invention there is provided an isolated polypeptide substantially as described above wherein the polypeptide is a functional fragment or variant of SEQ ID NO. 7 having at least 80% homology to SEQ ID NO. 7.

10 In a twenty-second aspect of the present invention there is provided an isolated nucleic acid molecule substantially as described above wherein the molecule is a functional fragment or variant of SEQ ID NO. 8 having at least 75% homology to SEQ ID NO. 8.

It is to be clearly understood that the invention also encompasses peptide analogues, which include but are not limited to the following:

- 15 1. Compounds in which one or more amino acids is replaced by its corresponding D-amino acid. The skilled person will be aware that retro-inverso amino acid sequences can be synthesised by standard methods; see for example Chorev and Goodman, 1993;
- 20 2. Peptidomimetic compounds, in which the peptide bond is replaced by a structure more resistant to metabolic degradation. See for example Olson *et al*, 1993; and
3. Compounds in which individual amino acids are replaced by analogous structures for example, gem-diaminoalkyl groups or alkylmalonyl groups, with or without modified termini or alkyl, acyl or amine substitutions to modify their charge.

25 The use of such alternative structures can provide significantly longer half-life in the body, since they are more resistant to breakdown under physiological conditions.

Methods for combinatorial synthesis of peptide analogues and for screening of peptides and peptide analogues are well known in the art (see for example Gallop et al, 1994; Hogan, 1997).

For the purposes of this specification, the term "peptide and peptide analogue" includes compounds made up of units which have an amino and carboxy terminus separated in a 1,2, 1,3, 1,4 or larger substitution pattern. This includes the 20 naturally-occurring or "common" α -amino acids, in either the L or D configuration, the biosynthetically-available or "uncommon" amino acids not usually found in proteins, such as 4-hydroxyproline, 5-hydroxylysine, citrulline and ornithine; synthetically-derived α -amino acids, such as α -methylalanine, norleucine, norvaline, C α - and N-alkylated amino acids, homocysteine, and homoserine; and many others as known in the art.

It also includes compounds that have an amine and carboxyl functional group separated in a 1,3 or larger substitution pattern, such as β -alanine, γ -amino butyric acid, Freidinger lactam (Freidinger *et al*, 1982), the bicyclic dipeptide (BTD) (Freidinger *et al*, 1982; Nagai and Sato, 1985), amino-methyl benzoic acid (Smythe and von Itzstein, 1994), and others well known in the art. Statine-like isosteres, hydroxyethylene isosteres, reduced amide bond isosteres, thioamide isosteres, urea isosteres, carbamate isosteres, thioether isosteres, vinyl isosteres and other amide bond isosteres known to the art are also useful for the purposes of the invention.

A "common" amino acid is a L-amino acid selected from the group consisting of glycine, leucine, isoleucine, valine, alanine, phenylalanine, tyrosine, tryptophan, aspartate, asparagine, glutamate, glutamine, cysteine, methionine, arginine, lysine, proline, serine, threonine and histidine. These are referred to herein by their conventional three-letter or one-letter abbreviations.

An "uncommon" amino acid includes, but is not restricted to, one selected from the group consisting of D-amino acids, homo-amino acids, N-alkyl amino acids, dehydroamino acids, aromatic amino acids (other than phenylalanine, tyrosine and tryptophan), ortho-, meta- or para-aminobenzoic acid, ornithine, citrulline, norleucine, α -glutamic acid, aminobutyric acid (Abu), and α - α disubstituted amino acids.

The term "polypeptide", "peptide" and "protein" are all used interchangeably herein to refer to a molecule comprising a chain of one or more amino acids.

The term "variant" as used herein refers to nucleotide and polypeptide sequences wherein the nucleotide or amino acid sequence exhibit:

- 5 - at least substantially 70%, or at least substantially 75% homology with the nucleotide or amino acid sequences contained in the sequence listing;
- preferably exhibits at least substantially 80% or 85% homology or greater with said sequences; and
- most preferably exhibits a homology selected from substantially 90-99%
- 10 homology to the sequences contained in the sequence listing and which may include at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology to said;

as assessed by GAP or BESTFIT (nucleotides and peptides), or BLASTP (peptides) or BLASTN (nucleotides). The variant may result from modification of the native
15 nucleotide, or amino acid sequence, by such modifications as; insertion, substitution or deletion of one or more nucleotides or amino acids, or it may be a naturally-occurring variant.

Thus, the term variant should be taken to include changes (i.e. conservative substitution) to the nucleotide sequences set forth herein which do not alter the amino acid being coded for, due to
20 the degenerate nature of the genetic code. The term "variant" also includes homologous sequences which hybridise to the sequences of the invention under standard, but most preferably under stringent conditions.

In general "stringent conditions" for determining the degree of homology may refer to:

- a) low salt concentrations (i.e. less than 1M, preferably less than 500mM and most
25 preferably less than 200mM); and

- b) high hybridization temperatures (i.e. at least 30°C, preferably greater than 37°C and most preferably greater than 50°C).

However, as the stringency of hybridization can be affected by other factors including probe composition and the presence of organism solvents, it is the combination of parameters above
5 that, which is important in determining stringency.

For example, stringent hybridization conditions can be defined as 2 x SSC at 65°C, or and for example standard hybridization conditions can be defined as 6 x SCC at 55°C, provided always that the variant is capable of diagnosing nematode infection. Where such a variant is desired, the nucleotide sequence of the native DNA is altered appropriately. This alteration can be
10 effected by synthesis of the DNA or by modification of the native DNA, for example, by site-specific or cassette mutagenesis. Preferably, where portions of cDNA or genomic DNA require sequence modifications, site-specific primer directed mutagenesis is employed, using techniques standard in the art.

The term "isolated" means substantially separated or purified away from contaminating
15 sequences in the cell or organism in which the nucleic acid naturally occurs and includes nucleic acids purified by standard purification techniques as well as nucleic acids prepared by recombinant technology, including PCR technology, and those chemically synthesised. Preferably, the nucleic acid molecule is derived from genomic DNA or the mRNA of the *Trichostrongylus colubriformis*.

20 The nucleic acid molecule may be an RNA, cRNA, genomic DNA or cDNA molecule, and may be single- or double-stranded. The nucleic acid molecule may also optionally comprise one or more synthetic, non-natural or altered nucleotide bases, or combinations thereof.

A fragment of a nucleic acid is a portion of the nucleic acid that is less than full length and comprises at least a minimum sequence capable of hybridising specifically with a nucleic acid
25 molecule according to the present invention (or a sequence complementary thereto) under stringent conditions as defined below. A fragment of a polypeptide is a portion of the polypeptide that is less than full length but which still retains a biological function of being

capable of diagnosing nematode infection. A fragment according to the invention has at least one of the biological activities of the nucleic acid or polypeptide of the invention.

The polypeptides of the invention can be prepared in a variety of ways. For example, they can be produced by isolation from a natural source, by synthesis using any suitable known
5 techniques (such as by stepwise, solid phase, synthesis described by Merryfield (1963), *J.Amer.Chem.Soc.* Vol 85:2149-2156) or as preferred, through employing DNA techniques.

The cloning vector may be selected according to the host or host cell to be used. Useful vectors will generally have the following characteristics:

- (a) the ability to self-replicate;
- 10 (b) the possession of an appropriately positioned single target for any particular restriction endonuclease; and
- (c) desirably, carry genes for a readily selectable marker such as antibiotic resistance.

Two major types of vector possessing these characteristics are plasmids and bacterial viruses (bacteriophages or phages). Presently preferred vectors include the bacteriophage lambda
15 Uni-ZAPTM XR and the modified plasmid pBAD18 vector, AY2-4. Tight regulation, modulation, and high-level expression are characteristics of vectors containing the arabinose PBAD promoter. *J. Bacteriol.* 177:4121-4130).

The DNA molecules of the invention may be expressed by placing them in operable linkage with suitable control sequences in a replicable expression vector. Control sequences may
20 include origins of replication, a promoter, enhancer and transcriptional terminator sequences amongst others. The selection of the control sequence to be included in the expression vector is dependent on the type of host or host cell intended to be used for expressing the DNA.

Generally, eucaryotic, yeast, insect or mammalian cells are useful hosts. Also included within the term hosts are plasmid vectors. Suitable procaryotic hosts include *E. coli*, *Bacillus* species
25 and various species of *Pseudomonas*. Commonly used promoters such as β -lactamase (penicillinase) and lactose (lac) promoter systems are all well known in the art. Any available

promoter system compatible with the host of choice can be used. Vectors used in yeast are also available and well known. A suitable example is the 2 micron origin of replication plasmid.

Similarly, vectors for use in mammalian cells are also well known. Such vectors include well known derivatives of SV-40, adenovirus, retrovirus-derived DNA sequences, Herpes simplex
5 viruses, and vectors derived from a combination of plasmid and phage DNA.

Further eucaryotic expression vectors are known in the art (e.g. P.J. Southern and P.Berg, *J. Mol. Appl. Genet.* 1 327-341 (1982); S. Subramani et al., *Mol.Cell.Biol.* 1, 854-864 (1981); R J. Kaufmann and P.A. Sharp, "Amplification and Expression of Sequences Cotransfected with a Modular Dihydrofolate Reducase Complementary DNA Gene, *J. Mol. Biol.* 159, 601-621 (1982);
10 R J. Kaufmann and P.A. Sharp, *Mol.Cell.Biol.* 159, 601-664(1982); S.I. Scahill et al., "Expressions And Characterization Of The Product Of A Human Immune Interferon DNA Gene In Chinese Hamster Ovary Cells," *Proc. Natl. Acad. Sci. USA.* 80, 4654-4659 (1983); G. Urlaub and L.A. Chasin, *Proc. Natl. Acad. Sci. USA.* 77, 4216-4220, (1980).

The expression vectors useful in the present invention contain at least one expression control
15 sequence that is operatively linked to the DNA sequence or fragment to be expressed. The control sequence is inserted in the vector in order to control and to regulate the expression of the cloned DNA sequence. Examples of useful expression control sequences are the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the glycolytic promoters of yeast acid phosphatase, e.g. Pho5, the promoters of
20 the yeast alpha-mating factors, and promoters derived from polyoma, adenovirus, retrovirus, and simian virus, e.g. the early and late promoters of SV40, and other sequences known to control the expression of genes of prokaryotic and eucaryotic cells and their viruses or combinations thereof.

A preferred promoter for use herein is the arabinose promoter (Guzman, L., Belin, D., Carson,
25 M. J. and Beckwith, J.,1995. Ref), however, any suitable promoter is included within the scope of the present invention as would be appreciated by a skilled worker.

In the construction of a vector it is also an advantage to be able to distinguish the vector incorporating the foreign DNA from unmodified vectors by a convenient and rapid assay. Reporter systems useful in such assays include reporter genes, and other detectable labels which produce measurable colour changes, antibiotic resistance and the like. In one preferred
5 vector, the β -galactosidase reporter gene is used, which gene is detectable by clones exhibiting a blue phenotype on X-gal plates. This facilitates selection. In one embodiment, the β -galactosidase gene may be replaced by a polyhedrin-encoding gene; which gene is detectable by clones exhibiting a white phenotype when stained with X-gal. This blue-white color selection can serve as a useful marker for detecting recombinant vectors.

- 10 The term "ligand" refers to any molecule which can bind to another molecule such as a polypeptides or peptide, and should be taken to include, but not be limited to, antibodies, cell surface receptors or phage display molecules.

The term "phage display molecule" refers to a molecule, such as a peptide, protein or antibody; expressed on the cell surface of a bacteriophage or like microorganism, by techniques well
15 known in the art.

It should be appreciated that the term "antibody" encompasses fragments or analogues of antibodies which retain the ability to bind to a polypeptide of the invention, including but not limited to Fr, F(ab)₂ fragments, scFv molecules and the like. The antibody may be polyclonal but is preferably monoclonal. In some embodiments the ligand may be a phage display
20 molecule.

"Primers" are short nucleic acids, preferably DNA oligonucleotides 15 nucleotides or more in length, which are annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and the target DNA strand, then extended along the target DNA strand by a polymerase, preferably a DNA polymerase. Primer pairs can be used for
25 amplification of a nucleic acid sequence, e.g. by the polymerase chain reaction (PCR) or other nucleic acid amplification methods well known in the art. PCR-primer pairs can be derived from the sequence of a nucleic acid according to the present invention, for example, by using

computer programs intended for that purpose such as Primer (Version 0.5[®] 1991, Whitehead Institute for Biomedical Research, Cambridge, MA).

“Probes” as used herein refers to a ligand which is labelled in some way (for example, radioactively, fluorescently or immunologically), and which are used to find and mark a target molecule by binding to the target molecule or a molecule associated therewith. In general, the target molecule may be a nucleic acid or polypeptide of the present invention, it may also include a polypeptide of the present invention when complexed (e.g. bound) to another ligand (such as for example an antibody), or the ligand when bound (i.e. associated with) the polypeptide.

- 10 For the purposes of this specification it will be clearly understood that the word “comprising” means “including but not limited to”, and that the word “comprises” has a corresponding meaning.

The present invention will now be described in detail, by way of reference only, to the following non-limiting examples.

15 **BRIEF DESCRIPTION OF SEQUENCE LISTING**

Further aspects of the invention will be apparent from the attached sequence listing, in which:

SEQ ID NO. 1 shows the amino acid sequence of *T.colubrifomis* Aspin (Tco-Aspin)

SEQ ID NO. 2 shows the nucleotide sequence of *T.colubrifomis* Aspin (Tco-Aspin)

SEQ ID NO. 3 shows the amino acid sequence of a truncated *T.colubrifomis* Aspin (Tco-Aspin*)

SEQ ID NO. 4 shows the nucleotide sequence of a truncated *T.colubrifomis* Aspin (Tco-Aspin*)

SEQ ID NO. 5 shows the amino acid sequence of *O.circumcincta* () Aspin (Oc-Aspin)

SEQ ID NO. 6 shows the nucleotide sequence of *O.circumcincta* Aspin (Oc-Aspin)

SEQ ID NO. 7 shows the amino acid sequence of *H.contortus* Aspin (Hc-Aspin)

SEQ ID NO. 8 shows the nucleotide sequence of *H.contortus* Aspin (Hc-Aspin)

BRIEF DESCRIPTION OF DRAWINGS

Further aspects of the present invention will become apparent from the following description which is given by way of example only and with reference to the accompanying drawings in which:

Figure 1 shows one-dimensional immunoblot analysis of *T. colubriformis* L3 homogenate proteins probed with time-course IgE samples from sheep during the development of immunity to nematode infection. IgE was purified from serum samples taken at various time-points following weaning of lambs in the field out to 18 months of age. Arrows indicate major antigen bands detected on immunoblots (I- 42 kDa, II- 31-32 kDa, III- 27-31 kDa, IV- 20-21 kDa, V- 2-14 kDa).

Figure 2 shows two-dimensional immunoblot analysis of *T. colubriformis* L3 homogenate proteins. Proteins were subjected to isoelectric focusing (left to right) followed by SDS-PAGE (top to bottom). Immunoblot was probed with affinity purified total IgE antibodies from pooled sera from immune sheep. Spot corresponding to Tco-Aspin is indicated by a circle and Tco-Aspin breakdown product by a square.

Figure 3 shows two-dimensional gel electrophoresis separation of *T. colubriformis* L3 homogenate total proteins Coomassie blue stained. Spot corresponding to Tco-Aspin is indicated by a circle and Tco-Aspin breakdown product by a square.

Figure 4 shows the alignment of Tco-Aspin with other members of the putative aspartyl protease inhibitor family. Database accession numbers for the previously sequenced members are: (Oo) *Ostertagia ostertagi* (CAD10783), (Pt) *Parelaphostrongylus tenuis* (AAG50205), (Ce) *Caenorhabditis elegans* (AAC46663), (Av) *Acanthocheilonema viteae* (S23229), (Di) *Dirofilaria immitis*

(AAA70419), (Ov) *Onchocerca volvulus* (AAA29419). Alignment begins at the putative initiating methionines. The conserved residues RDL of putative YVRDLT sequence motif suggested to be critical for inhibitor function are shown by *. Invariant cysteine residues are marked by ^.

5 Figure 5 shows one dimensional immunoblot of *T. colubriformis* adult homogenate (lane 1) and L3 homogenate (lane 2) immunostained with rabbit anti Tco-Aspin sera.

10 Figure 6 shows two-dimensional immunoblot analysis of *T. colubriformis* L3 homogenate proteins. Proteins were subjected to isoelectric focusing (left to right) followed by SDS-PAGE (top to bottom). Immunoblot was probed with serum from rabbit immunized with purified recombinant Tco-Aspin.

15 Figure 7 shows one-dimensional SDS-PAGE gel of affinity purified native Tco-Aspin stained with silver stain and corresponding immunoblot developed with rabbit anti Tco-Aspin sera.

20 Figure 8 shows one-dimensional SDS-PAGE gel transferred to PVDF of affinity purified native Tco-Aspin stained with Coomassie blue with segments excised for Edman sequencing (A) and corresponding immunoblot developed with rabbit anti Tco-Aspin sera (B)

EXPERIMENTAL

EXAMPLE 1

20 Nematode larvae and antigen preparation

Infective larvae (3rd stage) of *T. colubriformis* (TcL3) were obtained from cultures of faeces taken from monospecifically infected Romney sheep. Somatic antigen (TcL3-Homog) was prepared by homogenising exsheathed larvae under liquid nitrogen in a mortar and pestle. Soluble protein was extracted in 5 mM Tris buffer pH 7.6 with protease inhibitor (Complete, 25 Boehringer Mannheim) added. After centrifugation at 3000 rpm for 10 min, the protein

concentration of the supernatant was determined by absorbance at 230/260 nm, before being aliquoted and frozen at -70°C.

EXAMPLE 2

Two-dimensional gel electrophoresis

- 5 Sample preparation and isoelectric focusing was performed as described in the manufacturer's instruction manual with slight modifications. Briefly, 900 µl of TcL3-Homog (~360-1920 µg) was precipitated in 3600 µl acetone at -20°C for 30-120 min. After centrifuging at 17000g for 30 min at 4°C, acetone was removed and the precipitate dried. The precipitate was dissolved in ~280 µl of rehydration buffer containing 8 M urea, 3 M thiourea, 4% CHAPS, 40 mM dithiothreitol,
- 10 0.5% IPG buffer (pH 3-10 or pH 4-7) and a trace of bromophenol blue. The solution was used to rehydrate Immobiline DryStrips (13 or 18 cm, pH 3-10 or pH 4-7) at 30V for 30-60 hr on an IPGphor (Amersham Pharmacia Biotech). Proteins were focused at 20°C according to the following voltage protocol: 120V for 2 hr, 500V for 1hr, 1000V for 1 hr, 1000-8000V gradient for 30 min, 8000V for 6.0-8.5 hr (Total Vhr were 52000 to 80000 Vhr). After a standard
- 15 equilibration step, proteins were run in the second dimension on 10 to 18% linear SDS-Page gels. Proteins in the resolved gels were either stained with Copper (Bio-Rad) or microwave assisted Coomassie blue R-250 (Wong 2000) or transferred to nitrocellulose according to the manufacturer's directions (Bio-Rad).

EXAMPLE 3

20 Western blotting

- Proteins transferred to nitrocellulose were initially detected with Ponceau S (Harper & Speicher, 1995) and the membrane marked to assist later identification of proteins in gels for further analysis. All incubations were at room temperature and washing of membranes was with PBS + 0.05% Tween 20, 3 x 5 min. Following blocking with Blotto, nitrocellulose was probed with
- 25 purified sheep IgE (Shaw et al., 1997) at 10-15 µg ml⁻¹ overnight. IgE was obtained from sheep infected monospecifically with *T. colubriformis* or field grazing sheep and which showed high levels of immunity as determined by faecal egg count and worm counts (data not shown).

Membranes were incubated sequentially with mouse monoclonal anti-ovine IgE antibodies (XB6 & YD3 1/15 dilution of culture supernatant) and horseradish peroxidase-conjugated goat anti-mouse IgG gamma chain specific (1/1000) (Sigma Chemical) before detection with 3-Amino-9-ethylcarbazole. A protein spot corresponding to a strong IgE binding spot on Western blots with
5 molecular weight 33,000 and pI 5.1 (Tco-Aspin) was analysed to determine amino acid sequence information.

EXAMPLE 4

Protein in-gel digestion

Protein spots from Coomassie blue stained gels were identified by comparison with IgE stained
10 companion Western blots. Spots were excised, destained and digested with trypsin (Shevchenko et al., 1996). Briefly, spots were destained in 25 mM NH_4HCO_3 in 50% acetonitrile (ACN). Spots were then dried by centrifugal evaporation and rehydrated in 25mM NH_4HCO_3 containing 12.5 $\mu\text{g ml}^{-1}$ trypsin and incubated at 37°C for 16 hr. Peptides were then extracted sequentially with 25 mM NH_4HCO_3 , 50% ACN/0.5% trifluoroacetic acid (TFA)(3 times) and
15 100% ACN. The combined extracts were dried in a Speedvac, rinsed with milliQ water, then dried again. Extracts were then dissolved in 0.5%TFA. The tryptic digest was cleaned up with ZipTips (Millipore) according to the manufacturer's directions. Peptides were eluted from ZipTips in matrix solution consisting of a saturated solution of α -Cyano-4-hydroxycinnamic acid in 50% ACN/ 0.5% TFA and spotting directly onto Maldi sample plate.

20 EXAMPLE 5

Protein identification by peptide mass fingerprinting

Molecular masses of tryptic peptides from each protein spot were determined on a MALDI-tof instrument equipped with a nitrogen laser at 337 nm (Perceptive Biosystems, Voyager mass spectrometer). All MALDI spectra were externally calibrated using CALMIX 2. Peptide masses
25 were submitted for protein mass database searching at ProFound (URL: <http://www.proteometrics.com/prowl-cgi/ProFound.exe>).

EXAMPLE 6

De novo peptide sequencing by electrospray ionization

Protein spots were submitted to the Australian Proteome Analysis Facility (APAF, Sydney, Australia) for determination of amino acid sequence from selected peptides. Briefly samples
5 undergo a 16-hour tryptic digest at 37°C. The resulting peptides were purified using a ZipTip to concentrate and desalt the sample. The samples were then analysed by ESI-TOF MS/MS using a Micromass Q-TOF MS equipped with a nanospray source, using either flow injection coupled to a Waters CapLC, or manually acquired using borosilicate capillaries for nanospray acquisition. Data was acquired over the m/z range 400-1800Da to select peptides for MS/MS
10 analysis. After peptides were selected, the MS was switched to MS/MS mode and data collected over the m/z range 50-2000Da with variable collision energy settings. Amino acid sequences were then determined from this data.

EXAMPLE 7

N-terminal amino acid sequencing

15 Crude *T. colubriformis* L3 protein was separated by 2-D electrophoresis (as in EXAMPLE 2) and electroblotted to PVDF membrane using standard techniques for preparing proteins for sequencing. The PVDF was stained with 0.1% Ponceau S and or 0.025% Coomassie blue R the spots corresponding to allergens on companion Western blots (EXAMPLE 3) were identified and cut out. PVDF spots were then submitted for Edman degradation analysis to establish the
20 amino acid sequence of the amino terminus for as many residues as could be established.

EXAMPLE 8

Molecular Biology

The protein spot when subjected to QTOF mass spectrometry yielded the sequence of two peptides, TC41A and TC41I. Also the mature amino terminus of the protein was determined by
25 protein sequencing. Forward and reverse degenerate oligonucleotides were designed and used as primers in polymerase chain reaction (PCR) under permissive conditions. *T. colubriformis*

total RNA was prepared with Trizol (GibcoBRL) using manufacturers protocols except the initial extraction was performed by grinding larvae in presence of Trizol under liquid Nitrogen. Total RNA was converted to cDNA by standard procedures using SuperscriptII (GibcoBRL) and used as the template in subsequent PCR. The primers used in PCR are listed below.

- 5 SL1 GGTTTAATTACCAAGTTTGA
- Tco-Aspin* TC41Afor GAACAGCAGGAAATCACCAAYTTAYGARAA
- Tco-Aspin* TC41Arev TTTTCGTAGTTGGTGATTTCYTGYTGYTC
- Tco-Aspin* TC41Ifor GGAGARGCTGARCARTT
- Tco-Aspin* TC41Irev AAYTGYTCAGCYTCNCC
- 10 TC41.sig.5.nde GATCGGCGCGCCATATGGCACCAAGACAGAACGC
- Tco-Aspin* TC41.not.3 GATCTGCGGCCGCGCATAGATCCTCGTGCAGAAAGTT
- Tco-Aspin*.3.2.not GAATTCGCGGCCGCGCCTTCTTCTCAAACCTCCTTCAACTC
- Hc-Aspin 5.1 ATGAAGTTGGTCGTRCTSTGCGTTCTGTGTG
- HO-Aspin 3.1 ATAGATCCTTGTGCAAAAGTTGGGC
- 15 Hc-Aspin 3.RACE GCATGGTTCAGGGCAACAAGGTC
- Hc.Asprin.5.Nde GATCGGCGCGCCATATGCTCACTGTGGGCACGATCTCC
- Hc.Asprin.3.Not GATCTGCGGCCGCGCATAGATTCTCGTACAGAAAGTT
- Oc.Asprin.5.Nde GATCGGCGCGCCATATGCTTACTGTGGGCACAATCGCT
- Oc.Asprin.3.Not GATCTGCGGCCGCGCATAGATCCTTGTGCAAAAGTTG
- 20 PolyTA TTTTTTTTTTTTTTTTTTTTTTA
- PolyTC TTTTTTTTTTTTTTTTTTTTTTC

PolyTG TTTTTTTTTTTTTTTTTTTTG

PCR reactions were performed with *T. colubriformis*, *H. contortus*, and *O. circumcincta* cDNA with various combinations of these primers, in addition to the nematode spliced leader primer (SL1). PCR conditions using degenerate primers was as follows; 95° for 2', followed by 10
 5 cycles of 95° for 30sec, 35° for 45sec, + 1.0° per cycle, 72° for 45sec followed by 30 cycles of 95° for 30sec, 45° for 45sec, + 0.2° per cycle, 72° for 60sec, + 2sec per cycle. Utilizing *T. colubriformis* cDNA a product of 240bp was observed by agarose gel electrophoresis of products following reactions with the primer combination of SL1 and TC41Arev while all other combinations yielded no detectable PCR product. A product of 740bp was observed by agarose
 10 gel electrophoresis of products following reactions with the primer combination of SL1 and HO-Aspin 3.1 with the *O. circumcincta* cDNA template. A product of 700bp was observed by agarose gel electrophoresis of products following reactions with the primer combination of Hc-Aspin 5.1 and HO-Aspin 3.1 with the *H. contortus* template. The 3' end of *H. contortus* Aspin was generated by use of the primers Hc-Aspin 3.RACE and PolyTG in a PCR reaction with the
 15 *H. contortus* cDNA template. PCR products were cloned into pCR2.1 using TA cloning (Invitrogen) and sequenced using ABI 377 automated DNA sequencer (Waikato DNA sequencing facility). Analysis of the *T. colubriformis* sequence revealed homology to the 5' end of various nematode protease (pepsin) inhibitor mRNAs. It was also noted that a previously identified EST clone (unpublished) had homology to these protease (pepsin) inhibitors at the 3'
 20 end. This allowed the synthesis of Tco-Aspin specific 5' and 3' primers, TC41.not3 and TC41.sig.5.nde, each containing restriction endonuclease sites for cloning into the expression vector AY2-4. These primers were used to generate the mature Tco-Aspin coding sequence in a PCR reaction using *T. colubriformis* cDNA as template. The primers TC41.sig.5.nde and Tco-Aspin.3.2.not were used to generate truncated Tco-Aspin (Aspin*) coding sequence in a PCR
 25 reaction using *T. colubriformis* cDNA as template. The primers Hc.Asipin.5.Nde and Hc.Asipin.3.Not were used to generate the mature Hc-Aspin coding sequence in a PCR reaction using *H. contortus* cDNA as template. The primers Oc.Asipin.5.Nde and Oc.Asipin.3.Not were used to generate the mature Oc-Aspin coding sequence in a PCR reaction using *O. circumcincta* cDNA as template. After PCR the products were restricted with the appropriate

restriction enzyme and gel purified (Qiagen). The resultant DNA products were digested by appropriate restriction enzymes, cloned into the expression vector AY2-4 and the cloned insert was sequenced.

Bacteria containing either the Tco-Aspin/ AY2-4, Tco-Aspin*/ AY2-4, Hc-Aspin/ AY2-4 or Oc-Aspin/ AY2-4 construct were grown in LB broth at 37°C to an optical density (600nm) of 0.8 at which time protein synthesis was induced by the addition of 0.2% L(+)-arabinose (BDH). Induction proceeded for 16 hr at 30°C at which time the induced bacteria were pelleted and resuspended in 300mM NaCl/50mM P₀₄ pH 8.0 buffer containing 1mg/ml lysozyme and incubated on ice for 1 hr. The bacteria were sonicated and the solution clarified by centrifugation to yield a soluble bacterial fraction. Recombinant protein was immobilized to Ni-NTA resin (Qiagen), washed with 300mM NaCl/50mM P₀₄ pH 8.0 buffer containing 20mM imidazole to remove the contaminating *E. coli* proteins after which the recombinant protein was eluted by the addition of 100mM imidazole. The recombinant protein was subsequently dialyzed versus 300mM NaCl/50mM P₀₄ pH 8.0 buffer to remove the imidazole and the protein concentration determined. Recombinant Tco-Aspin was also purified from the insoluble, inclusion body fraction. In this case the bacterial pellet following centrifugation of the lysed bacteria was solubilised in 8M urea, 300mM NaCl/50mM P₀₄ pH 8.0 buffer and applied to the Ni-NTA column equilibrated in the same buffer. After washing with several column volumes, the column was washed in the same buffer without urea prior to elution in imidazole as above.

20 EXAMPLE 9

Immunisation of Rabbits

New Zealand white rabbits were immunized with purified 6-his tagged recombinant protein. Immunizing doses consisting of 100 µg of Tco-Aspin mixed with Montanide ISA50 at a ratio of 6 parts Montanide: 5 parts aqueous solution were injected intra muscularly and subcutaneously. Four weeks later a second immunizing dose prepared exactly as the first, was administered by the same route. The rabbit was bled by heart puncture under anesthetic 10 days after the second immunization. After clotting for 1 hour at room temperature the blood was centrifuged

at 1300g for 15 minutes. The serum was collected and stored at -20°C until needed. This serum is referred to as anti Tco-Aspin.

EXAMPLE 10

Affinity purification of native Tco-Aspin

5 IgG was purified from the sera of a rabbit immunised for Tco-Aspin by Protein G sepharose affinity using standard techniques. Purified antibody was bound to NHS-activated sepharose (Amersham Pharmacia) as per the manufacturer's protocols. TcL3-homog was passed through the immobilised rabbit antibody column at 0.5-2.0 ml/min. The column was washed with buffer (20 mM phosphate buffer, 500 mM NaCl, pH 7.0) until a baseline was reached at absorbance of
10 280 nm. The bound native Tco-Aspin was eluted with either 0.1M glycine or formic acid pH 3.0. The elutant was neutralised with 1M Tris or ammonium hydrogen carbonate pH 8.0. Eluted fractions were vacuumed dried before analysis by 1-D electrophoresis.

EXAMPLE 11

Enzyme immunoassay for specific IgE and IgG₁ to recombinant proteins

15 Antigen-specific IgG1 and IgE were detected by ELISA as described previously (Shaw et al 1998a). The optimal concentration of soluble recombinant for coating the plates with Tco-Aspin having the amino acid sequence SEQ ID NO. 1 was determined to be 0.2 and 5 $\mu\text{g ml}^{-1}$ in PBS for IgE and IgG1 assays respectively. To get an indication of antibody levels in field sheep, serum samples were obtained from AgResearch's selectively bred Romney sheep lines
20 selected for high (susceptible) or low (resistant) faecal nematode egg count. Samples were also taken at the same time from an unselected control flock. Results were expressed as mean absorbance in O.D. units. For statistical analysis antibody O.D values were $\log_e$ transformed to normalise the distributions.

Specific IgE immunoassay method:

25 Serum samples were pre-treated by precipitating 500 μl of serum with 500 μl of 76% saturated ammonium sulphate in distilled water. Samples were vortexed for 10 sec, repeated at 15 min,

and then after 30 min centrifuged in a microcentrifuge (10 min at 13,000 rpm). The supernatant was collected and diluted 1:1 in distilled water plus 0.1% Tween 20 in preparation for assay. Wells of microtiter plates (Costar EIA/RIA plate (#9017), Corning Incorporated, Corning, NY, USA) were coated for 2 hours at 37°C with optimally diluted recombinant Tco-Aspin ($0.2\mu\text{g ml}^{-1}$, 100 μl) in PBS pH 7.2. Following 3 washes with 0.05% (v/v) Tween 20 in distilled water (water-T20), plates were blocked for 5 min in 5% skim milk powder in PBS. Plates were washed 6 times in water-T20. Microtiter plates were then incubated with precipitated serum supernatant (100 μl per well in duplicate) overnight at room temperature. Following 6 washes in PBS-Tween 20, plates were incubated sequentially with mouse monoclonal antibody to ovine IgE (1/15 culture supernatant XB3/YD3, Shaw et al, 1998), goat anti-mouse gamma chain specific peroxidase conjugate (Sigma, St. Louis, Mo, USA). The enzyme substrate 3,3',5,5'-tetramethylbenzidine was added and incubated for 30 min. The reaction was stopped 2N H_2SO_4 . Plates were read using a 450 nm filter. A sheep was deemed Tco-Aspin IgE positive if its mean absorbance value was greater than 6 times the mean of assay blank wells plus 2 standard deviations.

EXAMPLE 12

Skin Testing

Skin testing was performed on AgResearch's 2002 born selectively bred Romney sheep lines. Monthly skin testing and serum sampling occurred from weaning until lambs were around 6 months of age (April 2003). Sheep were injected intradermally at either of two sites, the relatively wool-free area of the inside thighs, or occasionally the flank (after clipping of wool). Native or recombinant Tco-Aspin (0.1-10 μg) in PBS was injected using 26 gauge needles. Wheal and flare reactions were observed and measured approximately 30 min after injection. For the majority of the skin testing, 0.15-0.3 μg of Tco-Aspin was injected. The injection site located on the inside upper rear leg area has minimal wool coverage which aided injection and reaction evaluation. Using a tuberculin syringe with a 26 gauge x $\frac{1}{2}$ inch needle, 100 μl of PBS containing Aspin was injected intra-dermally. Typically if injected correctly, a small distinctive bubble formed at the injection site. The time and sheep tag number was then recorded.

Injection of other animals then continued for around 20 minutes. Reading of reactions was carried in the order of injection. The sheep were located, caught, turned over and injection site identified. Reactions were scored on a scale of 0-4 (Table 1). A score of 0 or 1 is regarded as negative. A score of 2 or more is regarded as positive.

- 5 Table 1. Value and description of scoring used to assess skin testing reaction.

Score	Description
0	No reaction
1	Slight swelling only (no reddening)
2	Large swelling & no reddening
3	Swelling, and reddening
4	Large swelling, red and heat

The reaction was measured using a vernier caliper by reading the longest diameter of the reaction wheal and its transecting diameter, in millimeters. The area of skin test reaction was calculated by multiplying these 2 values (mm²)

10 EXAMPLE 13

Pepsin inhibition assay

The inhibition of haemoglobin digestion activity of porcine pepsin (Kageyama 1998) was used to determine activity of native and recombinant Tco-Aspin. Pepstatin was used as a positive control.

15 Results and discussion

To identify allergenic proteins, TcL3-homogenate was separated electrophoretically, electroblotted and immunostained with affinity purified ovine IgE. Previous studies using 1-D SDS-Page gels had identified protein bands at approximate molecule weights of 12-14, 20-21, 27-31, 31-32 and 42 kDa as being associated with allergic immunity to *T. colubriformis* infections in field grazing sheep (Figure 1). Using 2-D electrophoresis technology, a protein spot corresponding to a strong IgE binding spot on Western blots with molecular weight 33,000 and pI 5.1 (Tco-Aspin) (Figure 2) was cut out from Coomassie blue stained 2-D gel (Figure 3) and analysed to determine amino acid sequence information. No positive match to known proteins was obtained using peptide mass fingerprinting with peptide masses obtained from the 33kDa/pI 5.1 spot. De novo peptide sequencing was possible from 2 tryptic peptides obtained from the isolated spot. These are; TC41A; 884.9 [M+2H]²⁺ SASEQQE[L/I]TNYEK and TC41I; 737.46 [M+3K]³⁺ GEAEQFL. A N- terminal sequence of LTVGTI was obtained by Edman degradation of the 33kDa/pI 5.1 spot following its transfer to a PVDF filter.

Preparation of recombinant Aspartyl protease inhibitor (Tco-Aspin)

Forward and reverse degenerate oligonucleotide primers were designed from the internal peptide sequences and used in PCR in combination with each other or with primers corresponding to the nematode splice leader sequence and polyT. A PCR product from *T. colubriformis* cDNA was obtained using the primers TC41Arev and SL1. This product was TA cloned (InVitroGen) into the plasmid pCR2.1 and the insert was sequenced. Analysis of the sequence revealed that this cDNA was from the same gene as a partial cDNA clone previously sequenced from a *T. colubriformis* cDNA library (unpublished). The overlapping, combined cDNAs encode a protein (Tco-Aspin) with strong homology to proteins of the aspartyl protease inhibitor family that contains the peptides identified by sequencing of the 33kDa/pI 5.1 spot (see below). The primers TC41.sig.5.nde and TC41.not.3 were synthesized based on DNA sequences at the amino- and carboxyl terminus of the Tco-Aspin coding region. These primers were used in a PCR with a *T. colubriformis* cDNA template to obtain a complete copy of the coding DNA for Tco-Aspin. The resultant PCR product was sequenced and cloned into the expression vector AY2-4 containing the arabinose promoter, a polyHis domain, and a monoclonal epitope tag. The plasmid was transfected into *E. coli* bacteria and successful

transfectants were identified by ampicillin resistance. The recombinant bacteria were grown in culture and induced for expression of Tco-Aspin with arabinose. Recombinant Tco-Aspin was found in both the soluble protein fraction and in the insoluble, inclusion body fraction following induction. The soluble Tco-Aspin was directly purified by immobilised metal affinity chromatography (IMAC). The insoluble fraction was solubilised in a chaotropic agent and then purified by IMAC.

Aspartyl protease inhibitor (Tco-Aspin)

This cDNA sequence of 684 base pairs (SEQ ID NO. 2) codes for a protein of 228 amino acids (SEQ ID NO. 1) with a predicted molecular mass of 25,414 Da and a calculated pI of 5.31. The N-terminus amino acid sequence contains a putative signal peptide (SignalP V1.1; <http://www.cbs.dtu.dk/services/SignalP/index.html>) with a suggested cleavage site between residues 15 and 16 (alanine-alanine). N-terminal sequencing showed that the mature protein's N-terminus is LTVGTI suggesting that further processing removes the amino acids APRQKR. The putative mature protein of 215 amino acids, without the signal sequence and amino acids APRQKR, would have a predicted molecular mass of 23056.77 Da and pI of 4.93. The sequence does not contain predicted N-glycosylation sites.

Computer searches with the predicted amino acid sequence revealed significant homologies with aspartyl protease inhibitors of *Ostertagia ostertagi* (CAD10783): (% identity/% similarity) (86%/90%), *Parelaphostrongylus tenuis* (AAG50205): (71%/83%), *Caenorhabditis elegans* (AAC46663): (50%/68%), *Acanthocheilonema viteae* (S23229): (40%/59%), *Dirofilaria immitis* (AAA70419): (42%/57%), *Onchocerca volvulus* (AAA29419): (42%/60%). A Clustal sequence alignment of Tco-Aspin with other members of the putative aspartyl protease inhibitor family is shown in Figure 4. These proteins share more distant homology to a known aspartyl protease inhibitor from the intestinal nematode *Ascaris suum* (Martzen et al, 1990). Structural features common to the nematode Aspins include the presence of a signal peptide sequence and the conservation of all four cysteine residues in the mature protein. The YVRDLT sequence motif, suggested as being of crucial functional importance in several filarial nematode inhibitors (Willenbacher J et al. 1993), is not well conserved in Tco-API-1 as this protein retains only a

shortened RDL motif at the equivalent position. Related inhibitors from *O. volvulus*, Ov33 (Tume et al. 1997) and *A. suum*, PI-3 (Martzen et al, 1990, Kageyama 1998) inhibit the in vitro activity of aspartyl proteases such as pepsin and cathepsin E. Using porcine pepsin, we were able to demonstrate a similar inhibitory activity with affinity purified native Tco-Aspin.

5 Rabbit antiserum to recombinant Tco-Aspin was applied to 1-D blots of TcL3 and Tc-adult homogenate (Figure 5). This identified strong staining bands in TcL3 homogenate at 31 and 22 kDa. Considerably weaker bands of the same molecular weights were seen on the adult homogenate. When rabbit antiserum produced to Tco-Aspin was applied to a 2-D blot of TcL3 homogenate, a series of closely placed spots of 32.2-34.5 kDa and pI 4.9-5.7 (Figure 6) were
10 identified. These correspond in localisation to the original spot submitted for amino acid sequencing. A spot at 58.8 kDa, pI 5.6 is thought to be non-specific binding. An additional spot at 22.9 kDa, pI 5.7 was stained with rabbit anti Tco-Aspin antiserum and considered to be a breakdown product of Tco-Aspin.

Affinity purified native Tco-Aspin isolated from crude TcL3-homogenate and run on 1-D SDS-
15 page gels (Figure 7) ran as 2 bands of molecular weight 31.3 and 21.8 kDa.

The 22 kDa antigen that was identified by probing of a 2-D blot of crude TcL3-homogenate, and that was affinity purified from the same material with rabbit anti-Tco-Aspin antibody, is probably a truncated product of Tco-Aspin. Attempts to identify this spot (see Figures 3 & 4: square) by amino acid sequencing techniques failed to produce a result due to insufficient amount of
20 protein in gels. An abundant neighbouring protein positioned below the 22 kDa Tco-Aspin truncated product on 2-D gels was submitted for amino acid sequencing. Following sequencing of the *T. colubriformis* DNA coding for this protein, it was shown as having homology to a *Caenorhabditis elegans* hypothetical protein Y5F2A.1. No significant IgE binding could be demonstrated to a recombinant version of this protein. Approximately 40 µg of affinity purified
25 native Tco-Aspin, was concentrated and loaded onto to a 1-D SDS-page gel. The gel was transferred to PVDF and stained to identify affinity purified products (Figure 8). Along with the 31 and 22 kDa protein bands, a third lower molecular weight band was also identified. Each of these three bands were excised and submitted for N-terminal sequencing. Edman sequencing

revealed that each had the same N-terminal amino acid sequence of LTVGTI. This shows that these proteins are truncated products of Tco-Aspin, likely generated by proteolytic cleavage at the C-terminal end and that the N-terminal end of Tco-Aspin is not degraded. Thus we conclude that the 20-21 kDa band identified by screening of sheep developing immunity to nematode infections (Figure 1) is a truncated product of Tco-Aspin.

In an effort to prepare a recombinant version of the 20-21 kDa truncated Tco-Aspin (Tco-Aspin*) an expression vector was generated expressing a Tco-Aspin peptide lacking the sixty-five amino acids C-terminal to the double lysines at position 164-165 of the protein sequence. The molecular weight of this peptide is proportional to that of native Tco-Aspin truncated product (20-21 kDa).

In developing an ELISA for Tco-Aspin, maximal reactivity with purified IgE from immune sheep was achieved with either soluble Tco-Aspin, or, after reduction, with both soluble and insoluble forms. Optimal protein concentration for coating microtitre plates was found to be $0.2 \mu\text{g ml}^{-1}$ for specific IgE assays and $2.5 \mu\text{g ml}^{-1}$ for specific IgG₁ assays using soluble Tco-Aspin. *Ostertagia circumcincta* (Oc-Aspin) (SEQ ID NO. 5), *Haemonchus contortus* (Hc-Aspin) (SEQ ID NO. 7) and truncated Tco-Aspin* (SEQ ID NO. 3) recombinant Aspins were also produced. Optimal protein concentration for specific IgE assays was found to be $0.25 \mu\text{g ml}^{-1}$ for Oc-Aspin and Tco-Aspin* and $5 \mu\text{g ml}^{-1}$ for Hc-Aspin.

Immunoreactivity of selection line sheep toward recombinant allergen

Specific IgE response to Tco-Aspin in nematode-infected sheep

IgE and IgG₁ responses to recombinant Tco-Aspin were measured in lambs from lines selectively bred for resistance (R) or susceptibility (S) to nematode parasite infection at AgResearch's Wallaceville Animal Research Centre (Morris et al., 2000). An unselected control (C) line was also maintained. Lambs from all three lines grazed together on worm-infected pasture. Table 2 shows that the R-line lambs had significantly higher levels of anti-Tco-Aspin IgE than did S- or C-line lambs in serum samples taken in January and March when the lambs were approximately four and six months of age. In contrast, anti-Tco-Aspin IgG₁ levels were

significantly different only between the R and S lines of sheep. These results show that specific IgE reactivity in lambs to the nematode allergen Tco-Aspin as early as 4 months of age can be used to identify animals that are better able to develop effective nematode worm immunity. 49% of R-line sheep were Tco-Aspin IgE positive in January and this increased to 58% by 5 March. By contrast, 3% and 5% of S-line lambs, and 18% and 28% of the control line, respectively, were positive in January and March. Very similar results were obtained for R-line samples when they were assayed on native Tco-Aspin (data not shown).

Table 2

Mean specific antibody results in January or March (Optical Density values, back-transformed) for Wallaceville Selection Line male lambs born in 2001.

Sheep Line	Tco-API-1 IgE Jan	Tco-API-1 IgE Mar	Tco-API-1 IgG ₁ Jan	Tco-API-1 IgG ₁ Mar	Number of sheep
Susceptible	0.001 ^a	0.049 ^a	0.559 ^b	0.300 ^a	37
Controls	0.022 ^a	0.047 ^a	0.641 ^{NS}	0.471 ^{NS}	49
Resistant	0.200	0.390	0.688	0.529	51

- 5 Test for Line difference from Resistant-Line sheep, where ^a $P < 0.001$; ^b $P < 0.05$; ^{NS} Not significant.

Consistent with the selection-line differences in Table 2, a strong negative genetic correlation (Table 3) was found between log transformed Tco-Aspin (IgE) and log transformed faecal egg count (FEC). For example, the genetic correlation of log_eTco-Aspin January (IgE+1) with
10 log_e(FECJanuary+100) was 0.44 (s.e. 0.12; $P < 0.001$), and with log_e(FECMarch+100) was 0.51 (s.e. 0.12; $P < 0.001$). (The genetic correlation indicates the degree to which genes controlling the expression of one performance measure in an animal are also associated with the expression of another performance measure.) No significant genetic correlations were
15 found between specific IgE response to Aspin and dag scores, and (not shown) no significant genetic correlations were found between anti-Tco-Aspin IgG1 levels and FEC at four or six months of age, or between anti-Tco-Aspin IgG1 levels and dag scores.

Table 3. Genetic correlations between measured antibody traits, skin-test traits and log_e Faecal Egg Count (FEC), breech soiling score (dag score) or live-weight gain (weaning to January, or January to April).

Genetic correlation with						
	log _e (FEC _{Jan} +10 0)	log _e (FEC _{Mar} +100)	Dag score (Jan)	1 Dag score	Gain (Wng to Jan)	Gain(Jan to Apr)
log _e (Tco-API-1 IgE _{Jan+1})	-0.44 s.e. 0.12 ^a	-0.51 s.e. 0.12 ^a	0.18 s.e. 0.16 ^{NS}	0.02 s.e. 0.16 ^{NS}	-0.25 s.e. 0.17 ^{NS}	-0.15 s.e. 0.18 ^{NS}
log _e (Tco-API-1 IgE _{Mar+1})	-0.37 s.e. 0.09 ^a	-0.44 s.e. 0.09 ^a	0.11 s.e. 0.12 ^{NS}	-0.04 s.e. 0.12 ^{NS}	-0.13 s.e. 0.13 ^{NS}	0.02 s.e. 0.14 ^{NS}
Skin test score (April)	-0.04 s.e. 0.14 NS	-0.16 s.e. 0.15 ^{NS}				
Negative/Positive score (April)	-0.08 s.e. 0.16 NS	-0.12 s.e. 0.17 ^{NS}				
log _e (Area _{April+1000})	-0.00 s.e. 0.15 NS	-0.15 s.e. 0.15 ^{NS}				

^a P<0.001

^{NS} - not significant

It was then hypothesised that Tco-Aspin and perhaps aspartyl protease inhibitors from other gastro-intestinal nematodes, might have efficacy in an intradermal skin test aimed at rapidly identifying sheep disposed to develop immune resistance to nematodes under field conditions. Table 4 shows that, from an evaluation of the skin test with 218 selection-line animals, those in the R, C and S lines responded significantly differently to the skin test, whether measuring allergic area, using a 0-4 score, or defining a negative/positive criterion for allergy. These three measures were also significantly negatively associated with FEC measured in six-month animals ($P < 0.063$ for area, and $P < 0.005$, at least for test score (0-4) and negative/positive test outcome). Table 4 also shows that the R-line animals were not significantly different in response from the resilient-line lambs (the latter being bred for their ability to continue growing without the need for anthelmintic treatment when under serious nematode challenge).

Table 4. Summary of least squares analyses on skin-test traits in ewe lambs, using area measurement, test score, and negative/positive response.

				Back-transformed		Transformed		Log FEC2
Trait name	No	Sig. effects	Line	LS area	mean	LS s.e.	mean area ±	cov. ^a
Log₁₀ (Area+1000)	67	Line, P < 0.0004	81 (Resistant)	249		7.130	s.e. 0.013	
	58		2 (Control)	181	**	7.074	s.e. 0.014	
	41		82 (Susceptible)	167	***	7.062	s.e. 0.016	
	52		85 (Resilient)	245	n.s.	7.127	s.e. 0.014	
	218							
						LS mean		
Test score (0 to 4) (Not transformed)	67	Line, P < 0.0003	81 (Resistant)			1.866	s.e. 0.124	
	58		2 (Control)	**	1.328	s.e. 0.133		
	41		82 (Susceptible)	***	1.122	s.e. 0.158		
	52		85 (Resilient)	n.s.	1.807	s.e. 0.140		
	218							
						LS mean		
Negative/Positive (Neg test=scores 0, 1; Pos test=scores 2 - 4)	67	Line, P < 0.0005	81 (Resistant)			0.642	s.e. 0.059	
	58		2 (Control)	**	0.362	s.e. 0.064		
	41		82 (Susceptible)	***	0.317	s.e. 0.076		
	52		85 (Resilient)	n.s.	0.596	s.e. 0.067		
	218							

^a Correlation (covariance) with log (FEC2) in Lines 2, 81 and 82 only;

5 ** $P < 0.01$; *** $P < 0.001$.

These results extend previous work in which we reported a negative genetic correlation between FEC and IgE responses of R- and S-line lambs exposed to nematode challenge while grazing (Shaw et al., 1999). However, unlike the previous work where specific IgE to a crude mixture of TcL3 ES antigens showed a positive genetic correlation to the level of breech soiling ("dag score") in March, there was no such correlation between Tco-Aspin specific IgE and dag score in the present study. This suggests that selection of sheep for resistance to parasite infection, based on increased specific IgE levels to Tco-Aspin, should not lead simultaneously to increased breech soiling. The formation of dags in the breech area is brought about by diarrhoea thought to be associated with inflammatory responses to nematode infections and is particularly evident on some resistant-line sheep (Bisset et al., 2001). We have thus confirmed that it is possible to establish more practical tests to measure IgE levels specific for defined allergens, apart from ELISA, and these may be used effectively as part of a selective breeding program.

Animal resources used in the studies for Tables 2- 4:

Table 2: (Least squares analysis)_137 born-2001 Resistant (R), Susceptible (S) & Control (C)-line ram lambs.

Table 3: (Genetic correlations from ASREML analyses)

Rows 1 & 2: ELISA results for b'89-91 (n=709) Progeny-Test lambs, plus b'2001 (n=592) lambs, with all FEC and Dag-score data at Wallaceville from 1979-2001. (N.B. no ASPinIgE(Jan) for b'89 Prog Test lambs; only March)

Rows 3-5: Skin test results for b'2002 lambs (223 Ewe lambs from all lines of ewe lambs at Wallaceville (Lines 2, 22, 42, 81, 82 & 85), plus 42 R-line ram lambs, with all FEC data from 1979-2002).

Table 4: (Least squares analysis) 218 ewe lambs from R, S, C and Resilience lines.

Comparison of Tco-Aspin Skin Test with specific IgE ELISA

Score correlation with ELISA: The association between skin test score, negative (score 0-1) or positive (score 2-4) and ELISA negative or positive (sample rated IgE positive if its mean absorbance value was greater than the mean of assay blank wells plus 2 standard deviations) was determined using Chi square test.

- 5 Table 5a. Ram lambs significance of association between score Neg/Pos and ELISA at different cut-offs (1 to 10 times the mean of the assay blank wells plus 2 standard deviations (Bkgd))

	16/12/0	21/01/0	25/02/0	18/03/0	17/04/0
Bkgd x	2	3	3	3	3
1	0.153	1.000	1.000	1.000	1.000
2	0.008 ^a	0.007 ^a	0.003 ^a	0.113	1.000
3	0.042 ^a	0.000 ^a	0.002 ^a	0.049 ^a	0.143
4	0.018 ^a	0.001 ^a	0.006 ^a	0.022 ^a	0.017 ^a
5	0.328	0.000 ^a	0.002 ^a	0.004 ^a	0.004 ^a
6	0.328	0.000 ^a	0.000 ^a	0.029 ^a	0.040 ^a
7	0.172	0.000 ^a	0.000 ^a	0.036 ^a	0.040 ^a
8	0.172	0.001 ^a	0.000 ^a	0.007 ^a	0.013 ^a
9	0.172	0.000 ^a	0.000 ^a	0.003 ^a	0.008 ^a
10	0.060	0.003 ^a	0.000 ^a	0.003 ^a	0.002 ^a

^a $P < 0.05$

- 10 Table 5b. Ewe lambs significance of association between score Neg/Pos and ELISA at different cut-offs (1 to 10 times the mean of assay blank wells plus 2 standard deviations (Bkgd))

	18/12/0	22/01/0	20/02/0	14/03/0	2/04/03
Bkgd x	2	3	3	3	
1	0.321	0.210	1.000	0.205	1.000
2	0.001 ^a	0.008 ^a	0.000 ^a	0.084	0.015 ^a
3	0.068	0.000 ^a	0.000 ^a	0.012 ^a	0.050
4	0.075	0.005 ^a	0.000 ^a	0.005 ^a	0.001 ^a
5	0.985	0.001 ^a	0.000 ^a	0.002 ^a	0.001 ^a
6	0.624	0.000 ^a	0.000 ^a	0.007 ^a	0.003 ^a
7	0.624	0.000 ^a	0.000 ^a	0.007 ^a	0.004 ^a
8	0.159	0.000 ^a	0.000 ^a	0.004 ^a	0.001 ^a
9	0.159	0.001 ^a	0.002 ^a	0.001 ^a	0.003 ^a
10	0.159	0.002 ^a	0.007 ^a	0.001 ^a	0.002 ^a

^a $P < 0.05$

Except at weaning (December), these results suggest that an ELISA value greater than four times the mean background value for an ELISA plus two standard deviations would be significantly associated with a positive skin test reaction.

The chi-square for scores (negative versus positive) falling in the top vs. bottom half of the rank list for ASP IgE (March) was 61.5 (i.e. $P < 0.0001$). Table 6 shows that log(ELISA IgE) and log(Skin test) are closely correlated ($P < 0.0001$) in samples taken on ewe or lambs at about 6 months of age.

- 5 Area correlation with ELISA: Prior to analysis, $\log_e(\text{Area measurement} + 100)$ and $\log_e(\text{corrected ELISA value} + 1)$ were calculated. The skin test measurement was analyzed using least squares, with sex as a fixed effect and $\log_e(\text{ELISA IgE})$ for the relevant date as a covariate.

Table 6. Test of the association (significance test) between log(ELISA IgE) and log(Skin test area in $\text{mm}^2 + 100$)

10

Date	Sex	N Records	R^2 accounted for by model	Significance test*	Regression of log(area+100) on log (ELISA IgE)
2/4/03, 18/3/03	Ewe + Ram	109	0.17	$P < 0.0001$	$0.79 \pm - 0.17$
17/4/03	Ram	42	0.43	$P < 0.0001$	$0.65 \pm - 0.11$

We conclude that ELISA IgE and Skin Reaction Area are significantly associated

The selection line differences in 2002 born lambs (Resistant vs Susceptible) for Aspin IgE, both January and March, were highly significant ($P < 0.0001$). The selection line differences in Area were significant ($P < 0.001$)

- 15 **Heritability of Aspin specific IgE ELISA and skin test**

Table 7

Heritability	
Aspin IgE (January)	0.1802 se 0.054 $P < 0.001$
Aspin IgE (March/April)	0.347 se 0.0662 $P < 0.0001$
Skin test score (April)	0.3857 se 0.1735 $P < 0.05$
Skin test Neg/Pos (April)	0.2808 se 0.1638 Not Significant
Skin test Area (April)	0.3421 se .01757 $P < 0.053$

These results show that both the ELISA and skin test are heritable traits

Comparison of different nematode Aspins

Coding sequence for Aspins from *O. circumcincta* (Teladorsagia circumcincta) and *H. contortus* was obtained and recombinant proteins expressed. The coding DNA was inserted into bacterial expression vectors and the corresponding recombinant proteins were produced and purified as described previously for Tco-Aspin. The amino acid sequences of the three Aspins are very similar. Homologies with Tco-Aspin for *Ostertagia circumcincta* are (% identity/% similarity) (87.1%/89.8%) and *Haemonchus contortus* (84.9%/87.6%)

Serum samples from Resistant line ram lambs born in 2001 were used to compare the reactivity of IgE to various native and recombinant Aspin preparations (Table 8).

Table 8. Specific IgE reactivity of 2001 born Resistant line ram lambs (N=48) in March 2001 to various Aspin preparations

	Rec. Tco- Aspin 1	Rec. Tco- Aspin 2	Rec. Tco- Aspin*	Native Tco-Aspin	Rec. Oc- Aspin	Rec. Hc- Aspin
Number positive	29	29	22	28	42	13
% positive	60.4	60.4	45.8	58.3	87.5	27.1

Native and recombinant Tco-Aspin identified around 58-60% of the resistant line ram lamb as Aspin IgE positive. Of those serum samples positive to native Aspin, recombinant Tco-Aspin and Oc-Aspin identified 96.4% and Hc-Aspin 42.9%. Oc-Aspin identified a further 27.1% serum samples as Aspin IgE positive. The truncated form of Tco-Aspin (Tco-Aspin*) identified 45.8%
5 of resistant line ram lambs, 71.4% of those animals identified by native Tco-Aspin. This comparison between Tco-Aspin & Tco-Aspin* suggests that most of the IgE epitopes are found on the truncated form of Tco-Aspin. We conclude that recombinant Tco-Aspin is as effective as native *T. colubriformis* Aspin in identifying Aspin IgE positive animals. Recombinant *O. circumcincta* may be of better use in that it identifies a greater number of sheep as Aspin
10 positive animals. *H. contortus* Aspin is less useful in identifying Aspin positive animals

Aspects of the present invention have been described by way of example only and it should be appreciated that modifications and additions may be made thereto without departing from the scope of the appended claims.

References

- Chandrashekar R, Masood K, Alvarez RM, Ogunrinade AF, Lujan R, Richards FO, Weil GJ. Molecular cloning and characterization of recombinant parasite antigens for immunodiagnosis of onchocerciasis. *J Clin Invest.* 1991; 88(5):1460-6.
- 5 Chandrashekar R, Ogunrinade AF, Weil GJ. Use of recombinant *Onchocerca volvulus* antigens for diagnosis and surveillance of human onchocerciasis. *Trop Med Int Health* 1996 Oct;1(5):575-80
- Choreo and Goodman, *Acc. Chem. REs.*, 1993 26 266-273
- Claerebout E, Geldhof P, Vercauteren I, De Maere V, Smith WD, Knox DP, Vercruysse J,
- 10 Identification of protective antigens of *Ostertagia ostertagi*. (Novel approaches meeting III (Mordun 1-5 July 2002)
- Dobson RJ, Waller PJ, Donald AD. Population dynamics of *Trichostrongylus colubriformis* in sheep: the effect of infection rate on the establishment of infective larvae and parasite fecundity. *Int J Parasitol.* 1990; 20(3):347-52.
- 15 Duffy MS, MacAfee N, Burt MD, Appleton JA. An aspartyl protease inhibitor orthologue expressed by *Parelaphostrongylus tenuis* is immunogenic in an atypical host. *Clin Diagn Lab Immunol* 2002 Jul;9(4):763-70
- Frank GR, Mondesire RR, Brandt KS, Wisnewski N. Antibody to the *Dirofilaria immitis* aspartyl protease inhibitor homologue is a diagnostic marker for feline heartworm infections. *J Parasitol*
- 20 1998 Dec;84(6):1231-6
- Freidinger, R.M., Perlow, D.S., Veber, D.F., *J. Org. Chem.* **1982**, 59, 104-109
- Gallop, M.A., Barrett, R.W., Dower, W.J., Fodor, S.P.A. and Hogan, Jr., J.C. *Nature Biotechnology*, 1997 15 328-330.

Harper S & Speicher DW. Detection of proteins on blot membranes. Current Protocols in Protein Science. 1995. 10.8.7.

Hong XQ, Santiago Mejia J, Kumar S, Perler FB, Carlow CK. Cloning and expression of DiT33 from *Dirofilaria immitis*: a specific and early marker of heartworm infection. Parasitology. 1996; 112 (3):331-8.

Kageyama T. Molecular cloning, expression and characterization of an *Ascaris* inhibitor for pepsin and cathepsin E. Eur J Biochem. 1998; 253(3):804-9.

Lucius R, Erondur N, Kern A, Donelson JE. Molecular cloning of an immunodominant antigen of *Onchocerca volvulus*. J Exp Med. 1988; 168(3):1199-204.

10 Martzen MR, McMullen BA, Smith NE, Fujikawa K, Peanasky RJ. Primary structure of the major pepsin inhibitor from the intestinal parasitic nematode *Ascaris suum*. Biochemistry. 1990; 29(32):7366-72.

Mejia SJ, Nkenfou C, Southworth MW, Perler FB, Carlow CK. Expression of an *Onchocerca volvulus* Ov33 homolog in *Dirofilaria immitis*: potential in immunodiagnosis of heartworm infection. Parasite Immunol. 1994; 16(6):297-303.

Morris, C.A., Vlassoff, A., Bisset, S.A., Baker, R.L., Watson, T.G., West, C.J., Wheeler, M. Continued selection of Romney sheep for resistance or susceptibility to nematode infection: estimates of direct and correlated responses. Animal Science 2000; 70: 17-27.

Nagai, U., Sato, K. *Tetrahedron Lett.* **1985**, 26, 647-650.

20 Olson et al., J. Med. Chem., 1993 36 3039-3049.

Sangster and Gill, Pharmacology of Anthelmintic Resistance Parasitology Today. 1999, Vol 15, No. 4

Shaw RJ, Grimmett DJ, Donaghy MJ, Gatehouse TK, Shirer CL, Douch PGC. Production and characterisation of monoclonal antibodies recognising ovine IgE. Veterinary Immunology and Immunopathology. 1996; 51: 3-4 235-251.

Shaw RJ, McNeill MM, Gatehouse TK, Douch PGC. Quantification of total sheep IgE concentration using anti-ovine IgE monoclonal antibodies in an enzyme immunoassay. *Veterinary Immunology and Immunopathology*. 1997; 57: 3-4 253-265.

Shaw RJ, Gatehouse TK, McNeill MM. Serum IgE responses during primary and challenge
5 infections of sheep with *Trichostrongylus colubriformis*. *International Journal for Parasitology*. 1998; 28: 2 293-302.

Shaw RJ, Morris CA, Green RS, Wheeler M, Bisset SA, Vlassoff A, Douch PGC. Genetic and phenotypic parameters for *Trichostrongylus colubriformis*-specific immunoglobulin E and its relationships with anti-*Trichostrongylus colubriformis* antibody, immunoglobulin G1, faecal egg
10 count and body weight traits in grazing Romney. *Livestock Production Science*. 1999; 58: 25-32.

Shevchenko A, Wilm M, Vorm O, Mann M, *Anal. Chem.* 1996, 68, 850-858

Smythe, M.L., von Itzstein, M., *J. Am. Chem. Soc.* **1994**, 116, 2725-2733

Van Wyk, Stenson, Van Der Merwe, Vorster, Viljoen. Anthelmintic Resistance in South Africa:
15 Surveys indicate an extremely serious situation in sheep and goat farming. 1999.

Waller, Anthelmintic Resistance. *Veterinary Parasitology*, 1997, 391-412.

Wong C, Sridhara S, Bardwell JCA, Jakob U. Heating greatly speeds Coomassie blue staining and destaining. *BioTechniques* 2000; 28:426-432.

Willenbacher J, Hofle W, Lucius R. The filarial antigens Av33/Ov33-3 show striking similarities
20 to the major pepsin inhibitor from *Ascaris suum*. *Mol Biochem Parasitol*. 1993; 57(2):349-51.

WHAT WE CLAIM IS:

1. An isolated polypeptide comprising:
 - a) an amino acid sequence as set forth in any one of SEQ ID NOs. 1, 3, 5 or 7; or
 - b) a functional fragment or variant of the polypeptides in a) above, wherein the fragment or variant provokes a humoral and/or cellular immunological response in an animal with similar characteristics to that produced by a polypeptide as outlined above.
2. An isolated polypeptide as claimed in claims 1 wherein the functional fragment or variant incorporates a B cell or T cell epitope of the polypeptide.
3. An isolated nucleic acid molecule wherein the molecule:
 - a) comprises a nucleotide sequence as set forth in any one of SEQ ID NOs. 2, 4, 6 or 8;
 - b) is a functional fragment or variant of the molecule(s) in a); or
 - c) is able to hybridise under stringent conditions to the molecule(s) in a) or b); or
 - d) is a complement of the molecule(s) defined in a), b) or c); or
 - e) is an anti-sense sequence corresponding to any of the sequences in a) – d).
4. An isolated nucleic acid molecule encoding a polypeptide as claimed in either claim 1 or 2.
5. A vector or construct comprising the nucleic acid molecule as claimed in claim 4.
6. A host cell which has been transformed with a vector or construct as claimed in claim 5.
7. An isolated ligand which binds to a polypeptide as claimed in either claim 1 or 2.

8. A probe capable of hybridizing under stringent conditions to a nucleic acid molecule as claimed in either claim 3 or 4.
9. A probe for a polypeptide as claimed in either claim 1 or 2.
10. A probe for the ligand of claim 7 when the ligand is bound to the polypeptide.
11. A method for determining the immune status of an animal to a nematode infection characterized by steps of:
 - a) obtaining a blood or serum sample from the animal;
 - b) preparing an IgE enriched or IgG depleted preparation of the sample in a);
 - c) contacting the sample at a) with a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs. 1, 3, 5 or 7 or a functional fragment or variant thereof;
 - d) contacting the preparation from c) with a probe for the immuno-complex formed by IgE and the polypeptide;
 - e) detecting the probe to identify the immune status of the animal by the presence or absence of the probe.
12. A method for determining the immune status of an animal to a nematode infection characterized by steps of:
 - a) obtaining a blood or serum sample from the animal
 - b) preparing an IgE enriched or IgG depleted preparation of the sample in a);
 - c) exposing the preparation from b) with a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs. 1, 3, 5 or 7 or a functional fragment or variant thereof;
 - d) washing the preparation from c) to remove any unbound IgE (i.e. IgE that is not bound to the polypeptide);

- e) detection of immuno-complex formed by the polypeptide and IgE at step c) with monoclonal antibodies to IgE.
 - f) detection of IgE with appropriately labeled anti-antibodies.
13. A method of determining the immune status of an animal comprising the steps of:
- a) exposing a portion of the animal's skin to a polypeptide comprising the amino acid sequence of SEQ ID NOs. 1, 3, 5 or 7 or a functional fragment or variant thereof;
 - b) determining the immune status by the presence or absence of an immune or allergic reaction.
14. A method for selectively breeding animals resistant to nematode infection characterized by steps of:
- a) determining the immune status of male and female animals;
 - b) selecting males and females disposed to develop immune resistance to nematodes;
 - c) using selected animals to breed progeny resistant to said infection.
15. An isolated polypeptide as claimed in either claim 1 or 2 wherein the polypeptide is a functional fragment or variant of SEQ ID NO. 5 having at least 90% homology to SEQ ID NO. 5.
16. An isolated nucleic acid molecule as claimed in claim 3 wherein the molecule is a functional fragment or variant of SEQ ID NO. 6 having at least 94% homology to SEQ ID NO. 6.
17. An isolated polypeptide as claimed in either claim 1 or 2 wherein the polypeptide is a functional fragment or variant of SEQ ID NO. 1 having at least substantially 75% homology to SEQ ID NO. 1.
18. An isolated nucleic acid molecule as claimed in claim 3 wherein the molecule is a functional fragment or variant of SEQ ID NO. 2 having at least substantially 70% homology to SEQ ID NO. 2.
19. An isolated polypeptide as claimed in either claim 1 or 2 wherein the polypeptide is a

functional fragment or variant of SEQ ID NO. 3 having at least 80% homology to SEQ ID NO. 3.

20. An isolated nucleic acid molecule as claimed in claim 3 wherein the molecule is a functional fragment or variant of SEQ ID NO. 4 having at least substantially 70% homology to SEQ ID NO. 4.
21. An isolated polypeptide as claimed in either claim 1 or 2 wherein the polypeptide is a functional fragment or variant of SEQ ID NO. 7 having at least 80% homology to SEQ ID NO. 7.
22. An isolated nucleic acid molecule as claimed in claim 3 wherein the molecule is a functional fragment or variant of SEQ ID NO. 8 having at least 75% homology to SEQ ID NO. 8.

FIG 1

Figure 1.




FIG 2

Figure 2.




FIG 3

Figure 3.

KDa

116

97

66

45

31

21

14.5

6.5




FIG 4

Figure 4

Nematode Aspin Homologues

Tco	MKLHLCVLCAIAFAAPRQKR---	LEVGTTIAVHGGAGCGCVVTGNVLYANGHFLRELTA	SECELTNYEKOVAEKAASK	75
Oo	MKLVLCVLCHLALAPRQKR---	LEVGTTIAVHGGAGCGCVVTGNVLYANGHFLRELTA	SECELTNYEKOVAEKAASK	75
Pt	MKLLHLCALIAFAAPRQKR---	LEVGTTIAVHGGAGCGCVVTGNVLYANGHFLRELTA	SECELTNYEKOVAEKAASK	75
Ce	MKLLALVALCAVAGSHDRQ---	LEVGTTIAVHGGAGCGCVVTGNVLYANGHFLRELTA	SECELTNYEKOVAEKAASK	84
Di	MKLLFCFVILLALALRASVINRHRKRFAGFVAG	LEVGTTIAVHGGAGCGCVVTGNVLYANGHFLRELTA	SECELTNYEKOVAEKAASK	79
Ov	MKLLFCFVILLALALRASVINRHRKRFAGFVAG	LEVGTTIAVHGGAGCGCVVTGNVLYANGHFLRELTA	SECELTNYEKOVAEKAASK	83
Av	MKLLFCFVILLALALRASVINRHRKRFAGFVAG	LEVGTTIAVHGGAGCGCVVTGNVLYANGHFLRELTA	SECELTNYEKOVAEKAASK	79
Tco	QILKERCEKLSRMSGKKETAAVSTK	LEDLKPKPKPSFCTEDDTTQYVFDGCMVQGNKVVGVNTVARDLIDQ	***	154
Oo	QALKERCEKLSRMSGKKETAAVSTK	LEDLKPKPKPSFCTEDDTTQYVFDGCMVQGNKVVGVNTVARDLIDQ	***	151
Pt	QALKERCEKLSRMSGKKETAAVSTK	LEDLKPKPKPSFCTEDDTTQYVFDGCMVQGNKVVGVNTVARDLIDQ	***	151
Ce	NILSGRENLENRMSOGRNQOQNDVSSQGGND	SELPKPKPKPSFCTEDDTTQYVFDGCMVQGNKVVGVNTVARDLIDQ	***	161
Di	TSLEERRKGWOLARHGEKTAIVLSLA	EKKPKPKPKPSFCTEDDTTQYVFDGCMVQGNKVVGVNTVARDLIDQ	***	155
Ov	ESLEERRKGWOLARHGEKTAIVLSLA	EKKPKPKPKPSFCTEDDTTQYVFDGCMVQGNKVVGVNTVARDLIDQ	***	158
Av	VSLEERRKGWOLARHGEKTAIVLSLA	EKKPKPKPKPSFCTEDDTTQYVFDGCMVQGNKVVGVNTVARDLIDQ	***	155
Tco	EIEELKEFEFKQTVQOEYVQKQIQOQVSNLFGGADFSSFFG	DAKDKQTTTVAIVLPEDAPEQAVPHECTRLY	^	228
Oo	EIEELKEFEFKQTVQOEYVQKQIQOQVSNLFGGADFSSFFG	DAKDKQTTTVAIVLPEDAPEQAVPHECTRLY	^	227
Pt	EIEELKEFEFKQTVQOEYVQKQIQOQVSNLFGGADFSSFFG	DAKDKQTTTVAIVLPEDAPEQAVPHECTRLY	^	226
Ce	EIEELKEFEFKQTVQOEYVQKQIQOQVSNLFGGADFSSFFG	DAKDKQTTTVAIVLPEDAPEQAVPHECTRLY	^	243
Di	EINLAKFEDAKMTAKYKYSIIQOQVDSLFQDKSNLENLFTDTR	HEITSSOP--SDATTISHTTQAPVEPEPEHECIAIY	^	234
Ov	EITOLKRFEDAKMTAKYKYSIIQOQVDSLFQDKSNLENLFTDTR	HEITSSOP--SDATTISHTTQAPVEPEPEHECIAIY	^	239
Av	EAKELKAFEDAKMTAKYKYSIIQOQVDSLFQDKSNLENLFTDTR	HEITSSOP--SDATTISHTTQAPVEPEPEHECIAIY	^	234

FIG 5

Figure 5




FIG 6

Figure 6

KDa

66

45

31

21

14.5

6.5




FIG 7

Figure 7





FIG 8

Figure 8



Nematode allergen August 2003 A.ST25.txt
SEQUENCE LISTING

<110> AgResearch Limited
Shaw, Richard John
McNeill, Margaret Mary
Maass, David Richard
Shoemaker, Charles Bix

<120> Novel Allergen

<130> 31230

<140> 521434

<141> 2002-09-13

<150> NZ 523777

<151> 2003-01-24

<160> 8

<170> PatentIn version 3.1

<210> 1

<211> 228

<212> PRT

<213> Trichostrongylus colubriformis

<400> 1

Met Lys Leu Ile Glu Leu Cys Val Leu Cys Ala Ile Ala Phe Ala Ala
1 5 10 15

Pro Arg Gln Lys Arg Leu Thr Val Gly Thr Ile Ala Val Thr Gly Gly
20 25 30

Val Gly Gly Ala Ser Gly Cys Val Val Thr Gly Asn Val Leu Tyr Ala
35 40 45

Asn Gly Phe Arg Leu Arg Glu Leu Ser Ala Ser Glu Gln Gln Glu Leu
50 55 60

Thr Asn Tyr Glu Lys Gln Val Ala Glu Tyr Lys Ala Ser Val Lys Gln
65 70 75 80

Ile Leu Lys Glu Arg Gln Glu Lys Leu Lys Ser Arg Met Ser Gly Lys
85 90 95

Lys Glu Glu Lys Ala Ala Val Thr Ser Thr Lys Asp Glu Asp Leu Pro
100 105 110

Lys Pro Pro Gln Lys Pro Ser Phe Cys Thr Glu Asp Asp Thr Thr Gln
115 120 125

Phe Tyr Phe Asp Gly Cys Met Val Gln Gly Asn Lys Val Tyr Val Gly
130 135 140

Asn Thr Phe Ala Arg Asp Leu Asp Gln Asn Glu Ile Glu Glu Leu Lys
145 150 155 160

Nematode allergen August 2003 A.ST25.txt

Glu Phe Glu Lys Lys Gln Thr Val Tyr Gln Glu Tyr Val Gln Lys Gln
 165 170 175

Ile Gln Gln Gln Val Ser Asn Leu Phe Gly Gly Ala Asp Phe Phe Ser
 180 185 190

Ser Phe Phe Gly Asp Ala Lys Asp Gln Thr Thr Thr Thr Val Ala Pro
 195 200 205

Val Leu Pro Glu Asp Ala Pro Glu Gln Pro Ala Val Pro Asn Phe Cys
 210 215 220

Thr Arg Ile Tyr
 225

<210> 2
 <211> 684
 <212> DNA
 <213> Trichostrongylus colubriformis

<400> 2
 atgaagttga tgcagctgtg tgttctgtgt gcaatcgctt ttgctgcacc aagacagaaa 60
 cgccttactg tgggcacgat tgctgtcacc ggaggggtcg gcggagcatc aggctgtgta 120
 gttactggaa atgttctcta tgcaaatggg ttccgccttc gcgagctcag cgcacgagag 180
 cagcaggaac tgacgaacta cgagaagcag gtggctgaat ataaagcgtc tgtgaagcaa 240
 atactcaagg agcgccagga aaaactgaag tctcgtatgt ccggttaagaa agaggagaag 300
 gctgccgtaa cttccacgaa ggacgaggac ttgccgaaac caccacaaaa gccctcattc 360
 tgcactgagg acgatacgac acaattctac tttgatggat gcatgggtca gggcaacaag 420
 gtctacgttg gcaacacatt cgcccgat ctggaccaga atgaaattga agagttgaag 480
 gagtttgaga agaagcagac tgtctatcag gactacgtcc agaagcaaat ccaacagcaa 540
 gtaagcaacc tcttcggtgg tgctgacttc ttctcatcat tctttggaga tgccaaggat 600
 cagactacca caactgtggc ccctgttctc cctgaagatg cccagaaca accagctgta 660
 ccgaacttct gcacgaggat ctat 684

<210> 3
 <211> 145
 <212> PRT
 <213> Trichostrongylus colubriformis

<400> 3
 Met Leu Thr Val Gly Thr Ile Ala Val Thr Gly Gly Val Gly Gly Ala
 1 5 10 15

Ser Gly Cys Val Val Thr Gly Asn Val Leu Tyr Ala Asn Gly Phe Arg
 20 25 30

Leu Arg Glu Leu Ser Ala Ser Glu Gln Gln Glu Leu Thr Asn Tyr Glu
 Page 2

Nematode allergen August 2003 A.ST25.txt

35

40

45

Lys Gln Val Ala Glu Tyr Lys Ala Ser Val Lys Gln Ile Leu Lys Glu
 50 55 60

Arg Gln Glu Lys Leu Lys Ser Arg Met Ser Gly Lys Lys Glu Glu Lys
 65 70 75 80

Ala Ala Val Thr Ser Thr Lys Asp Glu Asp Leu Pro Lys Pro Pro Gln
 85 90 95

Lys Pro Ser Phe Cys Thr Glu Asp Asp Thr Thr Gln Phe Tyr Phe Asp
 100 105 110

Gly Cys Met Val Gln Gly Asn Lys Val Tyr Val Gly Asn Thr Phe Ala
 115 120 125

Arg Asp Leu Asp Gln Asn Glu Ile Glu Glu Leu Lys Glu Phe Glu Lys
 130 135 140

Lys
 145

<210> 4
 <211> 435
 <212> DNA
 <213> Trichostrongylus colubriformis

<400> 4
 atgcttactg tgggcacgat tgctgtcacc ggaggggtcg gcggagcatc aggctgtgta 60
 gttactggaa atgttctcta tgcaaattgggt ttccgccttc gcgagctcag cgcattcggag 120
 cagcaggaac tgacgaacta cgagaagcag gtgggtgaat ataaagcgtc tgtgaagcaa 180
 atactcaagg agcgccagga aaaactgaag tctcgtatgt ccggttaagaa agaggagaag 240
 gctgccgtaa cttccacgaa ggacgaggac ttgccgaaac caccacaaaa gccctcattc 300
 tgcactgagg acgatacgac acaattctac tttgatggat gcatggttca gggcaacaag 360
 gtctacgttg gcaacacatt cgcccgtgat ctggaccaga atgaaattga agagttgaag 420
 gagtttgaga agaag 435

<210> 5
 <211> 227
 <212> PRT
 <213> Ostertagia circumcincta

<400> 5

Met Lys Leu Val Val Leu Cys Val Leu Cys Gly Ile Ala Leu Ala Ala
 1 5 10 15

Pro Arg Gln Lys Arg Leu Thr Val Gly Thr Ile Ala Val Thr Gly Gly
 20 25 30

Nematode allergen August 2003 A.ST25.txt

Val Gly Gly Ser Thr Gly Cys Val Val Thr Gly Asn Val Leu Tyr Ala
 35 40 45

Asn Gly Phe Arg Leu Arg Glu Leu Asn Pro Ser Glu Gln Gln Glu Leu
 50 55 60

Val Asn Tyr Glu Lys Gln Val Ala Asp Tyr Lys Ala Ala Val Lys Gln
 65 70 75 80

Ala Leu Lys Glu Arg Gln Glu Ser Leu Lys Ser Arg Met Ala Gly Lys
 85 90 95

Lys Glu Lys Ala Val Thr Pro Lys Glu Glu Asp Leu Pro Lys Ala Pro
 100 105 110

Gln Lys Pro Ser Phe Cys Thr Glu Glu Asp Thr Thr Gln Phe Tyr Phe
 115 120 125

Asp Gly Cys Met Val Gln Gly Asn Lys Val Tyr Val Gly Asn Thr Phe
 130 135 140

Ala Arg Asp Leu Asp Gln Asn Glu Ile Gln Glu Leu Lys Glu Phe Glu
 145 150 155 160

Lys Lys Gln Thr Val Tyr Gln Glu Tyr Val Gln Lys Gln Ile Gln Ala
 165 170 175

Gln Val Ser Asn Leu Phe Gly Gly Ala Asp Phe Phe Ser Thr Phe Phe
 180 185 190

Asn Gly Gly Ser Glu Lys Gly Ser Ser Thr Thr Thr Ala Ala Pro Val
 195 200 205

Leu Pro Asp Asp Ala Pro Glu Gln Pro Ala Val Pro Asn Phe Cys Thr
 210 215 220

Arg Ile Tyr
 225

<210> 6
 <211> 681
 <212> DNA
 <213> Ostertagia circumcincta

<400> 6
 atgaagtgg tcgtactgtg cggtctgtgt ggaatcgctc tcgctgcccc aagacagaaa 60
 cgccttactg tgggcacaat cgctgtcacc ggaggagtcg gcggatccac aggggtgtgtg 120
 gtgactggaa atgtgctcta tgcaaacggt ttccgccttc gtgagctcaa cccatcagag 180
 cagcaggaac tcgtgaacta tgagaagcaa gtggccgact acaaagcggc tgtgaagcaa 240
 gccctgaagg aacgccagga gagcctgaaa tcgcgtatgg ctggtaagaa ggagaaggct 300

Nematode allergen August 2003 A.ST25.txt

```

gtaactccca aagaggaaga cctaccaaaa gctccacaga agccctcatt ctgcactgag      360
gaagacacca ctcaattcta ttttgatgga tgcattggtc agggcaacaa ggtctacgtt      420
ggcaacacct tcgcgcgtga tttggaccag aacgagattc aagagttgaa ggagtttgag      480
aagaagcaga ctgtctacca ggaatacgtc cagaagcaga ttcaagcgca agtgagcaat      540
ctgttcggcg gtgccgactt cttctcgacg ttcttcaatg gcggatctga gaaaggctct      600
tccaccacca ccgcagctcc agtacttccc gatgatgcac cagaacaacc agctgtgccc      660
aacttttgca caaggatcta t                                              681

```

```

<210> 7
<211> 226
<212> PRT
<213> Haemonchus contortus
<400> 7

```

```

Met Lys Leu Val Val Leu Cys Val Leu Cys Gly Ile Ala Phe Ala Ala
1          5          10          15

```

```

Pro Arg Gln Lys Arg Leu Thr Val Gly Thr Ile Ser Val Thr Gly Gly
          20          25          30

```

```

Val Gly Gly Ser Thr Gly Cys Val Val Thr Gly Asn Val Leu Tyr Ala
          35          40          45

```

```

Asn Gly Phe Arg Leu Arg Glu Leu Thr Ser Ser Glu Gln Gln Glu Leu
          50          55          60

```

```

Val Asn Tyr Gly Lys Gln Val Ala Asp Tyr Lys Glu Ala Val Lys Lys
65          70          75          80

```

```

Ala Leu Lys Glu Arg Gln Glu Ser Leu Lys Ala Arg Met Ala Gly Lys
          85          90          95

```

```

Lys Glu Lys Ala Val Thr Pro Lys Glu Glu Asp Leu Pro Lys Ala Pro
          100          105          110

```

```

Glu Lys Pro Ser Phe Cys Thr Glu Asp Asp Thr Thr Gln Phe Tyr Phe
          115          120          125

```

```

Asp Gly Cys Met Val Gln Ser Asn Lys Val Tyr Val Gly Asn Thr Phe
          130          135          140

```

```

Ala Arg Asp Leu Asp His Asn Glu Ile Gln Glu Leu Lys Glu Phe Glu
          145          150          155          160

```

```

Lys Lys Gln Thr Val Tyr Gln Glu Tyr Val Gln Lys Gln Ile Gln Gln
          165          170          175

```

```

Gln Val Thr Asn Leu Phe Gly Gly Ala Asp Phe Phe Ser Ser Leu Phe

```

Nematode allergen August 2003 A.ST25.txt
 180 185 190

Asn Gly Ala Ser Lys Asp Ala Thr Thr Thr Thr Val Ala Pro Ala Leu
 195 200 205

Pro Asp Asp Ala Pro Glu Gln Pro Pro Val Pro Asn Phe Cys Thr Arg
 210 215 220

Ile Tyr
 225

<210> 8
 <211> 678
 <212> DNA
 <213> Haemonchus contortus

<400> 8
 atgaagttgg tcgtgctctg cggttctgtgt ggaatcgctt ttgcagcacc cagacagaag 60
 cgcctcactg tgggcacgat ctccgttact ggaggagtgt gtggttccac aggatgtgta 120
 gtaactggta atgtgcttta cgcaaatgga ttccgcctac gtgagcttac ttcacgga 180
 cagcaggaat tggtaaaacta tgggaagcag gtggctgatt ataaagaggc tgtgaagaag 240
 gctcttaagg agcgtcagga aagcctgaaa gcccgcatgg ctggtaagaa ggagaaggct 300
 gtgacgccta aggaggagga ctttcctaaa gcaccagaga agccatcatt ctgcactgag 360
 gatgatacta ctcaattcta cttcgatggc tgcattggtt agagcaacaa ggtctacgtt 420
 ggcaacacat tcgcccgtga tttggatcac aacgaaatcc aagagctaaa ggagttcgag 480
 aaaaaacaga cggcttacca agaatacgtc cagaagcaga tccaacagca agtaaccaac 540
 ctatttgggtg gtgctgactt cttctcatcc ctcttcaatg gtgcatcaaa ggatgctact 600
 accaccacgg tggctcctgc tcttcccgat gatgctcccg aacaaccacc tgtgcctaac 660
 ttctgtacga gaatctat 678

INTERNATIONAL SEARCH REPORT

International application No.
PCT/NZ03/00205

A. CLASSIFICATION OF SUBJECT MATTER					
Int. Cl. ⁷ : C12N 15/15, C07K 14/81, G01N 33/53					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols) SEE ELECTRONIC DATABASE BOX BELOW					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SEE ELECTRONIC DATABASE BOX BELOW					
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPIDS, CAPLUS, MEDLINE, BIOSIS: keywords: Aspin, aspartyl protease inhibitor, allergy, immune, infection, diagnosis. DGENE, PIR, SWISS-PROT, GENBANK: SEQ ID NOS: 1, 3, 5, 7.					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
T	Shaw R J <i>et al.</i> (2003) Int. J. Parasitol. 33: 1233-1243. " Identification and characterisation of an aspartyl protease inhibitor homologue as a major allergen of <i>Trichostrongylus colubriformis</i> ." See whole document.	1-6, 8, 9, 11-22			
P, X	De Maere V <i>et al.</i> (2002) Parasitology 125: 383-391. "Identification of potential protective antigens of <i>Ostertagia ostertagi</i> with local antibody probes." & EMBL database accession number CAD10783. See whole document.	1-6, 8, 9, 11-22			
☒ Further documents are listed in the continuation of Box C ☒ See patent family annex					
<table style="width: 100%; border: none;"> <tr> <td style="width: 33%; vertical-align: top;"> * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 33%; vertical-align: top;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family </td> <td style="width: 33%;"></td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family	
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family				
Date of the actual completion of the international search 26 November 2003		Date of mailing of the international search report - 3 DEC 2003			
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer JANE MCHENRY Telephone No : (02) 6283 2091			

INTERNATIONAL SEARCH REPORT

International application No.
PCT/NZ03/00205

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages (Remove spaces when completed if the page is too long)	Relevant to claim No.
X	WO 98/12563, A (HESKA CORPORATION) 26 March 1998. See whole document.	1-6, 8, 9, 11-22
X	WO 96/32641, A (NEW ENGLAND BIOLABS, INC) 17 October 1996. See whole document.	1-6, 8, 9, 11-22
X	Frank G R <i>et al.</i> (1998) J. Parasitol. 84(6): 1231-1236. "Antibody to the <i>Dirofilaria immitis</i> aspartyl protease inhibitor homologue is a diagnostic marker for feline heartworm infections." See whole document.	1-6, 8, 9, 11-22
X	Duffy M S <i>et al.</i> (2002) Clin. Diagn. Lab. Immunol. 9(4): 763-770. "An Aspartyl protease inhibitor orthologue expressed by <i>Parelaphostrongylus tenuis</i> is immunogenic in an atypical host." & EMBL database accession number AAG50205. 30 July 2002. See whole document.	1-6, 8, 9, 11-22
X	EMBL database accession number AAA70419. 25 July 1995. Wisnewski N <i>et al.</i> "Aspartyl protease inhibitor homolog". See whole document.	1-4 and 15-22

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ03/00205

Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos :
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos : 7 and 10 (completely) and 14 (in part)
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
See supplementary box below.

3. ☐ Claims Nos :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ03/00205

Supplemental Box

(To be used when the space in any of Boxes I to VIII is not sufficient)

Continuation of Box No: I

Claims 7 and 10 are unduly broad and speculative. These claims refer to a ligand which binds to a polypeptide of the invention or a probe for the ligand. A meaningful and economically feasible search could not encompass the complete subject matter of the claims. It is not clear to a skilled addressee what is encompassed within the scope of the term "ligand ". Therefore these claims have not been searched.

Claim 14 has not been fully searched. This claim refers to a method for selectively breeding animals resistant to nematode infection. The claim does not define all the technical features of the invention in so far as the claim is not limited to the use of the Aspin polypeptides or nucleic acids of the invention. Therefore the claim has only been searched with respect to the method using the polypeptides or nucleic acids of the invention.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/NZ03/00205

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
(To put a line under the citations tab to the first point on the next row and press F8)							
WO 9632641	EP	0820590 A4	JP	11503609 T	US	6103484 A	
	EP	0820590 A1	WO	9632641 A1			
WO 9812563	AU	43537/97 A	EP	0934529 A1	JP	2001502896 T	
	US	6391569 B1	US	2003170749 A1	WO	9812563 A1	
END OF ANNEX							

(To add more lines press TAB at end of last row, remove paragraph marker to join up 'END OF ANNEX' box)

专利名称(译)	天冬氨酰蛋白酶抑制剂作为线虫过敏原		
公开(公告)号	EP1546333A1	公开(公告)日	2005-06-29
申请号	EP2003748809	申请日	2003-09-12
[标]申请(专利权)人(译)	奥维塔有限公司		
申请(专利权)人(译)	OVITA有限公司		
当前申请(专利权)人(译)	OVITA有限公司		
[标]发明人	MCNEILL MARGARET MARY SHAW RICHARD JOHN MAASS DAVID RICHARD		
发明人	MCNEILL, MARGARET, MARY SHAW, RICHARD, JOHN MAASS, DAVID, RICHARD SHOEMAKER, CHARLES, BIX, TUFTS SCHOOL VET.MEDICINE		
IPC分类号	C07K14/81 C12N15/15 G01N33/68 G01N33/53		
CPC分类号	G01N33/6854 C07K14/8103 G01N2333/4353		
优先权	521434 2002-09-13 NZ 523777 2003-01-24 NZ		
其他公开文献	EP1546333A4		
外部链接	Espacenet		

摘要(译)

本发明广泛涉及新的线虫过敏原 (多肽) 和相关的氨基酸和核苷酸序列, 包括其功能片段和变体, 以鉴定能够对线虫产生天然抗性的动物。特别地, 本发明涉及这些分子的用途, 有助于选择性繁殖能够对线虫感染产生天然抗性的动物。更具体地说, 本发明涉及核酸分子和多肽的用途, 所述核酸分子和多肽是天冬氨酰蛋白酶抑制剂的相同或功能变体: (Tco-Aspin), 毛圆线虫 (Trichostrongylus colubriformis); 和/或 (Oc-Aspin), Ostertagia circumcincta; 和/或 (Hc-Aspin) 捻转血矛线虫 (Haemonchus contortus) 用于鉴定天生更多地处理线虫的动物。